How about today’s Uranium profile? It went completely parabolic before hitting resistance at the $5 level. The 52 week high is not too far off. It was up over 20% for most of the session.
We have a new profile that we want you to research ahead of Wednesday’s session.
One of the key catalysts is the massive reverse split that took place just a few weeks back on August first.
This puts the float currently under 6 million.
Artificial intelligence is transforming the landscape of modern healthcare — and few companies are embracing that shift as decisively as Healthcare Triangle Inc. (NASDAQ: HCTI).
As the global AI healthcare market accelerates toward nearly $188 billion by 2030, growing at a projected 38.6% CAGR (GrandView Research), the race to fuse data, automation, and intelligence for better patient outcomes is well underway. HCTI isn’t just participating — it’s leading from the front.
With a market capitalization under $20 million, the California-based innovator is executing a focused, fast-moving growth plan: acquiring cutting-edge AI technologies, expanding internationally, and building healthcare systems that turn raw data into actionable insights.
Its pending Teyame. AI acquisition, expected to contribute $34 million in annual revenue and $4.2 million in EBITDA, positions HCTI as a next-generation healthcare powerhouse — one capable of transforming compliance-grade infrastructure into smart, multilingual engagement and real-time analytics.
The company’s QuantumNexis AI platform already integrates data across research, clinical, and administrative silos — linking every part of the healthcare ecosystem under one intelligent, digital network. Alongside recent acquisitions like Niyama Healthcare and Ezovion Solutions, HCTI is assembling a full-stack platform that delivers automation, scalability, and seamless engagement.
Even its financial strategy reflects discipline: a strategically structured 2.8 million warrant inducement led by WallachBeth Capital brought in new funding while aligning long-term investors — avoiding the heavy dilution that often plagues small-cap companies.
With AI adoption accelerating worldwide and hospitals demanding secure, intelligent solutions, HCTI’s timing is impeccable.
HCTI drives advancements in healthcare through innovative technology and deep industry expertise. The company partners with hospitals, health systems, payers, and pharma/life sciences organizations to enhance patient outcomes by optimizing their use of data and information technology.
They have earned HITRUST Certification for their Cloud and Data Platform (CaDP), known in the market as CloudEz™ and DataEz™. Achieving HITRUST Risk-based, 2-year (r2) Certified status underscores the company’s commitment to maintaining the highest standards of data protection and information security.
By empowering healthcare enterprises to adopt modern technologies, gain data-driven insights, and stay agile in an evolving market, Healthcare Triangle helps them respond effectively to business challenges and competitive pressures. Operating within highly regulated healthcare and life sciences environments, the company provides trusted expertise in digital transformation, covering cloud enablement, security and compliance, data lifecycle management, healthcare interoperability, and clinical and operational performance optimization.
Timing Is Everything
What makes HCTI especially interesting right now is its instinct for timing. The market is overflowing with AI hype, yet very few companies can translate the noise into tangible results. HCTI can. Its technology isn’t theoretical; it’s built on HITRUST-certified cloud and data platforms that already serve healthcare and life sciences clients where compliance is non-negotiable. It has the infrastructure, credentials, and customers — and now, with the pending Teyame deal, it may have the ignition spark it needed.
A Layer of Intelligence
Teyame’s platform integrates seamlessly with HCTI’s architecture, acting as an intelligent layer that transforms static data into live, dynamic dialogue. It doesn’t just secure compliance — it makes it conversational. For hospitals and health systems drowning in untapped information, this combination could finally make their data speak. HCTI isn’t just managing digital transformation; it’s humanizing it. That distinction is what separates a routine service provider from a true market-maker.
Execution Over Excuses
Of course, words are easy. What makes HCTI stand out is that it executes. The company didn’t merely announce its AI ambitions — it followed through by rebalancing its finances to support sustainable growth. It’s running a strategy that merges imagination with discipline, innovation with accountability. Investors have noticed: the stock has climbed over 30% in five weeks, not on hype but on visible traction and renewed confidence.
Small but Significant
It’s easy to overlook companies of HCTI’s size. The market often equates scale with value. History, however, tells a different story — the innovators who reshape industries often start small and punch above their weight. HCTI feels like it’s entering that early, formative phase — when potential turns into presence. The numbers may still be modest, but the ambition is unmistakably large.
Leading With Proof, Not Promises
HCTI’s leadership understands that while perception can move prices, only proof sustains them. With its AI acquisition strategy, strengthened capital position, and disciplined cost management, the company has achieved a rare trifecta for a microcap: relevance, control, and credibility. Those qualities don’t show up directly on financial statements — but they’re exactly what institutional investors look for when the smallcap market heats up again.
The New Narrative: Evidence Over Echo
The shift in this market cycle is clear — proof has replaced promise as the ultimate currency. The winners won’t be the loudest or the largest; they’ll be the ones who can verify results. After years as a behind-the-scenes healthcare IT provider focused on cloud compliance and security, HCTI is proving that those same foundations can power a next-generation AI engine for engagement and growth.
Healthcare Triangle Subsidiary QuantumNexis Reports $20M in Consumption-Based Revenue Processed on Ezovion Platform, Forecasts $37M Amid Rapid Growth
PLEASANTON, Calif., Oct. 1, 2025 /PRNewswire/ — Healthcare Triangle, Inc. (Nasdaq: HCTI) (“HCTI” or the “Company”), a leader in digital transformation solutions for healthcare and life sciences, today announced a significant milestone for its wholly-owned subsidiary, QuantumNexis.
QuantumNexis’s Ezovion Electronic Medical Record (EMR) platform has processed over $20 million in revenue generated by healthcare providers who rely on the platform to digitize and manage their operations. This milestone underscores Ezovion’s expanding role as the digital infrastructure powering hospitals, clinics, and specialty care providers across multiple markets, enabling seamless digitization, streamlined workflows, and improved patient outcomes.
As QuantumNexis accelerates its global expansion into India, Bangladesh, Saudi Arabia, and Malaysia, the total revenue processed through the platform by end users is projected to surge from $20 million to $37 million over the next six months. This growth reflects both rapid adoption by new customers and deeper engagement by existing healthcare providers who are expanding their digital footprints.
Suresh Venkatachari, Chairman of QuantumNexis, said, “Crossing $20 million in end-user revenue shows the trust providers place in Ezovion. With global expansion, we expect this to reach $37 million in six months. Our upcoming payment gateway will let QuantumNexis directly monetize this growth through recurring revenue.”
The Ezovion platform operates on a consumption-based model, scaling alongside its customers as they expand their digital healthcare ecosystems. This approach fosters predictable demand, deeper engagement, and long-term relationships, while setting the stage for future monetization.
Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle Inc, added,
“As customer consumption grows, so does QuantumNexis. The payment gateway enhances this model, unlocking high-volume recurring revenue and positioning HCTI for global scale and long-term value.”
QuantumNexis will soon launch its proprietary integrated payment gateway, representing a pivotal evolution in the company’s business model. The gateway will enable QuantumNexis to earn 0.05% five basis points) of all revenue processed through the platform, creating a direct, scalable revenue stream from the substantial transaction volume flowing through Ezovion.
Kasi Shanmugam, Head of Technology at QuantumNexis, stated,”Our gateway has been engineered with advanced security and scalability, seamlessly integrating clinical and financial workflows. This will support rapid, secure adoption as we expand globally.”
By embedding payment processing directly into clinical workflows, QuantumNexis eliminates friction for healthcare providers while capturing recurring transaction-based revenue that scales automatically with platform growth.
Strategic Impact for Shareholders
The QuantumNexis milestone and payment gateway launch create multiple value growth drivers for HCTI:
$20M+ in end-user revenue already processed through the Ezovion platform, demonstrating strong market traction and platform adoption.
Projected growth to $37M in end-user revenue within six months, driven by aggressive international expansion and deeping customer engagement with existing customers.
Launch of an integrated payment gateway to directly monetize transaction flows, transforming platform activity into predictable recurring revenue for HCTI.
Strategic positioning as a hybrid SaaS + fintech company, creating a differentiated investment thesis that appeals to both healthcare technology and fintech-focused institutional investors.
Initial payment gateway deployments planned for late 2025, with comprehensive global scaling throughout 2026.
David Ayanoglou, Chief Financial Officer of Healthcare Triangle Inc, concluded,
“The rapid increase in end-user revenue processed through Ezovion reflects strong adoption and engagement by healthcare providers. By launching our payment gateway, HCTI can transform this activity into direct, recurring revenue while driving margin expansion and delivering long-term shareholder value.”
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY HCTI AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
***Sponsored by LFG Equities Corp and Disseminated on Behalf of Uranium Royalty Corp
AI has hit a power wall that only nuclear can break through
UROY has 25 interests in 22 uranium projects at various stages including large producers such a McArthur River and Cigar Lake and they already own 2.4 Million pounds of Uranium — Some of the Most Well Known Producing Mines in the World
The Pure Play on Uranium Royalties — Without the Risks of Mining
Back in May President Trump signed Executive Orders that include a policy objective to quadruple United States Nuclear Energy by 2050.
There is no doubt that 2025 has been very good to the mining sector, especially here in America with the new administrations focus on tackling the energy crisis and putting the other concerns to the side.
You might not be familiar because we are usually talking Gold, Silver, Oil, Copper etc. But what about Uranium, the precious Element that sits in the background while powering a large portion of what we need to move forward as a society.
The U.S. government designated Uranium a critical mineral, recognizing its importance to energy independence and limited secure supply sources. It is more than that though….. It is a strategic energy mineral due to its role in national energy, security and defense. It powers our nuclear reactors.This next one is the only listed pure-play uranium royalty company and they are generating millions in revenue right now.
Artificial intelligence is evolving at lightning speed, but all that intelligence comes with an enormous appetite for energy. Every new model, every powerful data center, and every smart application requires vast amounts of electricity to run. As AI becomes the backbone of modern innovation, we’re facing a simple truth: the future of AI depends on the future of energy.
That’s where nuclear power comes in. Unlike traditional energy sources, nuclear delivers clean, consistent, and carbon-free electricity 24/7. It doesn’t depend on sunshine or wind, making it the perfect match for data centers that can’t afford downtime. With new modular reactors on the horizon, nuclear power can scale alongside the rapid growth of AI — powering everything from model training to advanced robotics without adding pressure to our already strained grids.
For forward-thinking investors and innovators, this convergence of AI and nuclear energy represents one of the most exciting frontiers of the 21st century. It’s not just about keeping the lights on — it’s about building the resilient, sustainable infrastructure that will drive the next wave of technological progress. The companies that harness this synergy today will define the digital economy of tomorrow.
Since 2022, the global uranium market has entered a new phase — one defined by geopolitical tension, supply disruption, and renewed strategic importance.
Russia’s invasion of Ukraine reshaped the world’s nuclear fuel supply chain. With Rosatom, Russia’s State Atomic Energy Corporation, serving as a key supplier of nuclear fuel, Western nations are now facing mounting economic sanctions, transport barriers, and legislation restricting imports of Russian uranium.
Both the United States and European Union are accelerating efforts to reduce and ultimately eliminate dependence on Russian nuclear fuel, creating a structural shift in global uranium demand.
As utilities in the U.S. and Europe pivot toward secure, low-risk sources of supply, the stage is set for producers and royalty holders in stable jurisdictions — like Canada and the United States — to emerge as primary beneficiaries.
The U.S. Presidential Executive Order on “National Energy Dominance” further reinforces this momentum, emphasizing the goal to “reduce dependency on foreign imports” in the interest of “national security.” Within this policy framework, uranium has been explicitly recognized as a vital national asset — essential to America’s clean energy and defense future.
As the world races to secure nuclear fuel independence, UROY stands at the intersection of energy security and opportunity — a pure play on the transformation of the global uranium market.
The U.S. only has 94 operating nuclear reactors total. And a full one-third of them have already sold their power or are in talks with tech companies to provide them with power.
The left shows America’s 94 nuclear reactors, built decades ago and scattered across empty land. The right shows America’s 2,847 data centers.
The beating heart of the AI revolution will be powered by Nuclear. By 2030, both maps will look like the one on the right.
But tech companies aren’t waiting for the bogged down utilities to catch up. They’re doing something unprecedented: installing reactors directly at their data centers.
These aren’t the massive, concrete monoliths of the past — they’re small modular reactors (SMRs), compact nuclear units that can be built and deployed in as little as three to five years. Think of them as the “Lego blocks” of energy: scalable, efficient, and perfectly matched to the relentless power demands of AI.
Each SMR can provide a steady, carbon-free power supply that runs 24/7 — exactly what AI infrastructure needs to stay online, train models, and deliver services without interruption. For data center operators, that means energy independence, predictable costs, and a smaller environmental footprint. For investors, it means being part of the next great leap in both energy and technology — a fusion of innovation that’s rewriting the rules of what’s possible.
Concentrated: No transmission losses, no grid dependence
Compact: Critical when data center land costs $2M/acre
Constant: 24/7 uptime, no weather dependence
Every one of those SMRs — all 18 gigawatts currently in development, equal to roughly 20% of America’s entire nuclear fleet — depends on a single, irreplaceable input: uranium.
Here’s the problem: the U.S. produces only about 5% of the uranium it consumes. The rest — a staggering 95% — is imported, much of it from Russia, Kazakhstan, and other unstable suppliers who could turn off the tap at any moment.
Now picture what happens when Google, Microsoft, and Amazon realize their next-generation reactors — the very systems meant to secure their AI future — rely on uranium controlled by foreign powers.
The last time the world faced a uranium crunch, prices skyrocketed from $7 to $140 a pound. But that was before tech giants were building fleets of private reactors. This time, the demand shock could be unlike anything the energy market has ever seen.
Energy is so scarce that Meta recently signed a deal to fund 1.1 GW from an Illinois reactor………. But not to use the power, just to make sure the plant stays open until they need the power.
President Donald Trump recently unveiled Project Stargate, a massive $500 billion initiative designed to cement U.S. leadership in artificial intelligence. The project is a joint venture between OpenAI, Oracle, SoftBank, and other major technology and investment partners, with an initial $100 billion already committed. Its goal is to build a new generation of AI super-infrastructure across the United States — from advanced data centers and high-performance compute facilities to the energy systems required to power them.
OpenAI needs 10 gigawatts for just Stargate alone. That’s the equivalent of about 10 nuclear reactors. They put the cart before the horse and will exacerbate they already growing energy problem.
In 2025, the world will need 193 million pounds of uranium — but we’re only producing 165 million. That’s already a 28-million-pound shortfall.
And that’s before a single new AI data center switches on.
Now add Meta’s Manhattan-sized data campus, Amazon’s nuclear purchases, Microsoft’s reactor plans, and Google’s atomic ambitions. The deficit doesn’t just widen — it explodes.
Meta’s recent partnership with Constellation Energy includes a detail almost no one is talking about, a 20-yr PPA operating the Clinton plant that keeps output dedicated/contracted.
Yes — plants once shuttered, written off, and left for scrap are suddenly being revived. Why? Because a social media company needs more power to train language models.
The energy landscape isn’t just shifting — it’s being rewritten by AI’s insatiable demand for electricity. And uranium is rapidly becoming the most strategic resource in that story.
The Pure Play on Uranium Royalties — Without the Risks of Mining
Uranium Royalty Corp isn’t a miner. They don’t dig holes, manage crews, or worry about operating costs.
Instead, they own the toll booths of the uranium industry — collecting royalties whenever uranium moves from the ground to the reactor.
The Company has assembled a portfolio of royalty interests on uranium projects and physical uranium holdings.
While others shouldered the heavy lifting, UROY positioned itself to profit from the global nuclear energy revival — with none of the operational risk.
During the downturn, when sentiment around nuclear was at its lowest, Uranium Royalty Corp went on the offensive — acquiring physical uranium and royalty interests in some of the world’s most valuable uranium assets, including:
McArthur River and Cigar Lake mines in Saskatchewan, Canada — two of the world’s largest and highest-grade uranium producers, and key suppliers of fuel for North American reactors.
Now, as demand for clean, reliable nuclear power accelerates, UROY stands to benefit directly from rising uranium prices and increasing production — without mining a single ton.
Their Net Profit Interest (NPI) royalty model — proven successful for decades in the gold and silver industries — gives Uranium Royalty Corp. a share of project profits after costs, creating scalable exposure to uranium upside with minimal downside.
UROY offers up a leveraged play on the global uranium cycle — backed by world-class assets, disciplined timing, and a proven royalty model.
The Company’s long-term strategy is to gain exposure to uranium prices by owning and managing a portfolio of geographically diversified uranium interests, including uranium royalties and streams, debt and equity investments in uranium companies and holding physical uranium from time to time. In executing this strategy, the Company seeks interests that provide it direct exposure to uranium prices, without the direct operating costs and concentrated risks that are associated with the exploration, development and mining of uranium projects.
In addition to its existing portfolio of royalties and its strategic partnership with Yellow Cake, the Company’s primary focus is to identify, evaluate and acquire the following:
royalties in uranium projects, pursuant to which the Company would receive payments from operators of uranium mines based on production and/or sales of uranium products;
uranium streams, pursuant to which the Company would make an upfront payment to a project owner or operator in exchange for long-term rights to purchase a fixed percentage of future uranium production
off-take or other agreements, pursuant to which the Company would enter into long-term purchase agreements or options to acquire physical uranium products; and
direct strategic equity or debt investments in companies engaged in the exploration, development and/or production of uranium.
UROY believes that the advantages of this business model include:
Lower Volatility Through Diversification. By investing in diversified uranium interests across a spectrum of geographies, the Company reduces its dependency on any one asset, project, location or counterparty.
Exposure to Uranium Price Optionality without Project Costs and Overhead. The Company believes that its model provides exposure to any future improvements in the uranium market, while at the same time minimizing fixed operating, exploration, development and sustaining costs associated with directly owning and operating uranium projects. Additionally, as the Company’s interests are non-operational, the Company is not required to satisfy cash calls in order to maintain its interests in such projects.
Focus and Scalability. As the Company’s directors and officers do not handle operational decisions and tasks relating to uranium projects, they are free to focus their time and energy on carrying out the Company’s acquisition strategy and identifying and executing on growth opportunities. As such, URC’s business model allows it to acquire and manage more uranium interests than an operating company can effectively manage.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY UROY AWARENESS CAMPAIGN.
Dedicated Investors has received the funds indirectly from Katusa. Katusa Research partner company, New Era Publishing Inc. has received cash compensation in the amount of $1.25M from Uranium Royalty Corp and is thus extremely biased. Katusa Research, and its directors, employees, and members of their households directly own or may own shares of Uranium Royalty Corp (UROY/UROY.TSX). Therefore, Katusa Research is extremely biased. Measures are in place such that no shares will be sold during the active awareness campaign.
Please see additional disclosure information from our indirect sponsor Katusa here:
NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
ANTIBODIES AND VACCINES ARE OUTDATED: NanoViricides, Inc has a more innovative approach that works even when viruses mutate
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
___________________________
Hello Everyone,
The markets just exploded through all time highs and small caps are starting to catch fire as we finish out the last quarter of 2025 with this new administration that is highly favorable to entrepreneurship.
This next one is a past winner that trades in a tight channel and has a lot of support at its current levels.
NanoViricides, Inc. (NNVC) is pioneering a breakthrough approach to antiviral drug development with its lead candidate NV-387, currently advancing through Phase II clinical trials. This first-in-class compound has demonstrated exceptional efficacy in preclinical models against Influenza, RSV, COVID-19, MPox, and Smallpox—consistently outperforming leading antivirals such as Tamiflu, Remdesivir, and Tecovirimat.
NV-387 introduces a revolutionary “empiric therapy” paradigm that could transform how viral infections are treated. Unlike traditional antivirals, NV-387 allows physicians to begin treatment immediately—without waiting for viral identification. This capability positions NV-387 to capture a multi-billion-dollar global market, estimated at over $20 billion for broad-spectrum respiratory antivirals alone.
In addition, NV-387 is being evaluated for MPox treatment in Africa under preliminary regulatory authorization, with plans to extend these studies to Smallpox under the FDA’s Animal Rule pathway. Success in these areas could establish NNVC as a key global player in pandemic preparedness.
The company is pursuing Orphan Drug Designations and Priority Review Vouchers (PRVs)—which could translate into exclusive market access, accelerated approval timelines, and substantial non-dilutive revenue streams through voucher monetization.
Beyond NV-387, NNVC is advancing NV-HHV-1, targeting Shingles, Chickenpox, and HSV infections, as well as novel anti-HIV therapies that have shown best-in-class efficacy in humanized models.
The company’s proprietary nanoviricide platform mimics the natural virus-binding sites on host cells, enabling it to neutralize viruses before they can infect—a mechanism that bypasses traditional resistance pathways. This platform has the potential to address dozens of viral diseases, from Ebola and Dengue to seasonal influenza, offering broad and scalable commercialization opportunities.
With a fully operational cGMP manufacturing facility, a strong global IP portfolio, and a clear roadmap of value-driving milestones for 2025–2026—including Phase II results, new IND filings, and orphan drug approvals—NanoViricides is poised to deliver transformational growth and long-term shareholder value.
In an era of increasing viral threats, NNVC stands at the forefront of next-generation antiviral innovation—offering investors a rare opportunity to participate in a company with both scientific depth and exponential market potential.
NV-387 – A novel broad-spectrum antiviral
Since it is a potential cure for RSV infection, and since there is no non-toxic drug for general treatment of RSV infection at present; NV-387 meets an unmet need.
A therapeutic for treating measles is a completely missing link in the response the the current measles virus outbreak; NV-387 could meet this unmet need too.
The anti-Influenza activity of NV-387 given orally was substantially superior to all three of the approved anti-influenza drugs (Tamiflu, Rapivab, and Xofluza).
Bird flu is rampant in poultry in the USA leading to hen culling and soaring egg prices, resulting in a race to find a treatment that works; NV-387 can address it.
Long COVID also remains a problem for an estimated 17 million adults; an effective antiviral such as NV-387 has already delivered successful Phase 1 results.
While smallpox is eradicated in the USA, contagious monkeypox has appeared but there is no effective drug treatment for it and competitors clinical trials have failed; NV-387 is entering Phase 2 clinical trials for it.
NanoViricides, Inc. (NYSE American: NNVC)’s lead drug candidate NV-387 (drug product NV-CoV-2), a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials in healthy subjects with no reported adverse events, even at the highest and repeated dosages. Remarkably, NNVC has been able to develop NV-387 for oral administration already, as well as for injectable and inhalation formulations to enable many modes of use. The Company is currently focused on advancing NV-387 into Phase II human clinical trials for the treatment of RSV infection.
Susceptible viruses CANNOT escape NV-387, even as they continue to evolve in the field into variants. Why? Because no matter how much the virus changes, it continues to use the same host-side signature to bind to and cause infection in the hosts, and thus the nanoviricide would be anticipated to continue to be effective even as the virus mutates to generate variants.
Thus NV-387 and other antiviral drugs designed on the nanoviricides platform can be expected to have decades of effective usability against the target viruses similar to the life of current antibiotics against bacterial infections but in stark contrast to current antiviral approaches.
A broad-spectrum antiviral drug such as NV-387 would be a highly desirable drug globally because it would enable treatment by physicians of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. This is reminiscent of how antibiotics are prescribed, without specific infectious agent identification, relying on the ultra-broad-spectrum of the drug.
NV-387’s Extremely Broad Antiviral is a Host Mimetic That Acts As a Decoy To Attract And Trap Many Diverse Viruses, Preventing the Virus from Replication and Reinfection of Other Cells
Over 90% of human pathogenic viruses are known to use one or more “landing sites” that are in the Sulfated Proteoglycans (“SPG”) family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses.
NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. We have accumulated substantial evidence that in lethal viral infection animal studies, NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents.
Superior to Other Treatments?
NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus, as reported earlier. We believe that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections.
In treating Influenza, NV-387 was substantially superior to the three approved drugs, namely Tamiflu®, Rapivab® , and Xofluza® against an Influenza H3N2 lethal lung viral infection study, as previously reported. We believe that NV-387 is expected to possess strong antiviral activity against H5N1 “Bird Flu” as well, given that H5N1 viruses are known to bind to heparan sulfate proteoglycans, and based on the observed broad-spectrum activity of NV-387.
NNVC has also found that NV-387 is capable of completely curing a lethal RSV lung virus infection in animals, leading to indefinite survival of the animals, as reported recently. There is no cure for RSV, and no approved drug for treatment of RSV infection other than the toxic last-resort drug ribavirin.
Moreover, even novel viruses, whether from natural sources or bio-engineered, are expected to be susceptible to NV-387 if they employ SPG for gaining access to human cells to infect and cause disease. Thus, NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics.
NV-387 could thus be a single drug to treat all of the “tripledemic” viruses (COVID, RSV, FLU ), and more, when so approved!
Finally, NV-387 was at least as effective as the approved drug tecovitrimat (TPOXX®, SIGA), in a lethal intra-digital infection by ectromelia virus in mice. Importantly, a combined drug made from NV-387 and tecovirimat was more effective than either drug alone, indicating NV-387 “plays well” with tecovirimat and acts by a different mechanism.
Smallpox poses a significant biodefense threat. Ectromelia virus is a native virus of mice in the poxvirus family and is one of the key animal model viruses for developing smallpox therapeutics. Tecovirimat is an approved drug for treating smallpox infection based on the FDA “Animal Rule”, and is stockpiled by the US “Strategic National Stockpile”. It was mobilized during the recent monkeypox epidemic.
It is important to develop additional smallpox therapeutics that work well with tecovirimat and by themselves, since viruses pose the threat of drug escape by mutation; further, in a bio-terrorism scenario, a human-engineered smallpox virus resistant to existing drugs could be a potential threat.
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides
SHELTON, CONNECTICUT / ACCESS Newswire / October 22, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in cell culture studies as well as in a humanized animal model. Additionally, NV-387 treatment led to protection of lungs which is very important for keeping severely ill patients alive in late-stage viral infections. Currently, there is no approved drug for treating Measles.
Firstly, NV-387 was found to have direct antiviral effects against Measles virus in standard cell culture-based testing that measured increase in the extent of surviving infected cells upon treatment with the drug (i.e. “CPE” or Cytopathic Effects Assay).
Additionally, in a lethal Measles infection humanized animal model, NV-387 treatment led to a substantial increase in the number of survival days, to 17 days in NV-387-treated animals, from only 7.4 days in untreated animals, an increase of 130%, in a lethal lung infection of humanized mice by Measles virus1, as previously reported.
The increased survival correlated with several improvements in the animal health indicating control of viral infection:
Slow disease progression, and mild to moderate levels of lung damage as observed in microscopic histopathology.
Protection of lungs was also evident from the significant reduction in the level of lung plaques (damage to lung tissue) compared to untreated cases.
Reduction in the level of lung-damaging lymphocytes and neutrophils attracted into the lungs (i.e. infiltration).
These observations indicated that NV-387 treatment led to beneficial effects that protected lungs as well as reduced overall systemic infection.
We have thus found that NV-387 has dual benefits of (i) directly reducing the virus itself, together with (ii) protecting systemic cellular damage, and in particular, protecting lungs from viral damage as well as self-inflicted damage from killer cells.
These benefits make NV-387 an unusual and highly desirable antiviral drug.
NV-387 has completed Phase I clinical trial in healthy subjects with no reportable adverse events, and was found to be safe and well tolerated. In IND-enabling studies, NV-387 was found to be extremely safe and well tolerated in animal models. NV-387 was found to be non-immunogenic, non-allergenic, non-mutagenic, and non-genotoxic.
NV-387 acts by a unique mechanism of action that we call “Re-Infection Inhibition”. NV-387 is designed as a mimic of heparan-sulfate proteoglycan (HSPG) structures that are used by over 90% of human pathogenic viruses as “attachment receptor(s)”, in order to congregate close to cells before being able to bind to the virus’s direct receptors on cells (called the “cognate receptors”) and fusing into the cell. NV-387 “looks like” a cell to the virus, displaying copious amounts of the fragments that mimic HSPG on the nanoviricide micelle surface. This fools the virus into binding to the NV-387, whereupon the shape-shifting NV-387 engulfs the virus, causes lipid-lipid fusion with the virus surface, destroying its ability to infect cells.
NV-387 is available as Oral Gummies, which dissolve slowly in the mouth; and do not require swallowing. Swallowing can be difficult for a patient in presence of a rash.
With Measles outbreaks spreading all across the country, the USA is expected to lose the Measles elimination status, and the virus would be considered endemic thereafter as it was before 2000. Vaccination against Measles is effective, but there are limitations to its public health potential. Measles is extremely contagious, and more than 95% population needs to be vaccinated to eliminate the disease. To complicate the matters, persons with weakened or otherwise affected immune systems do not benefit from vaccination because their immune system cannot mount response to the challenge.
Further, it has become clear in recent years that the Measles virus is drifting from the current vaccine strain (circa 1968) over the last fifty-plus years, and there is some evidence that some variants may have arisen that have greater resistance to the vaccine than in the past.
Thus a drug for combating this emerging infectious disease of Measles is important. As a Company, we note that regulatory development of a drug specific for Measles is not cost-effective, and we will continue to seek non-dilutive grants and contracts support for further development of NV-387 as a treatment for Measles.
NV-387 can be readily developed for Measles through FDA licensure, because it is a multi-purpose, broad-spectrum antiviral. NV-387 is being developed to treat several different viral infections acquired by the respiratory route.
NanoViricides is working on regulatory development of NV-387 as a treatment for viral infections that include RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, as well as the epidemic-threatening virus causing MPox and the bio-terrorism threat virus of Smallpox.
A Measles Drug with Strong Activity without Toxicity Can Be Available Now for Emergency Use, Says NanoViricides – NV-387 Broad-Spectrum Antiviral with Activity Against Measles Virus
SHELTON, CT / ACCESS Newswire / October 20, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), announced that its clinical lead drug NV-387 has shown strong activity against the Measles virus in a humanized animal model. The Company announces that NV-387 can now be made available for emergency use application in Measles patients to respond to the spreading Measles outbreaks.
Having a drug to treat patients has become of paramount importance, in view of the fact that the USA is about to return to an endemic playground for the Measles virus, with over 1,600 cases as of October 17, breaking a thirty-year-plus-long record this year1.
“We have already developed an effective drug to respond to the Measles virus outbreaks spreading all across the country,” said Anil R. Diwan, PhD, President.
“NV-387 can be used right away for emergency use in Measles cases,” said Krishna Menon, VMD, MRCS, PhD, Consulting Scientist (Non-Clinical), adding, “With my extensive experience with non-clinical development of several marketed drugs, I can definitely say that NV-387 has excellent activity and safety in treating Measles virus infection.”
Dr. Menon designed and conducted the humanized animal model studies for testing drugs against Measles virus infection. As such, he has hands-on experience with the effects of the drug NV-387. The data has provided compelling evidence that NV-387 is indeed highly effective in protecting the infected from the systemic effects of Measles infection.
“The drug is manufactured under GMP in the USA,” added Jayant Tatake, PhD, Vice President of the Company.
NV-387 has already completed Phase I clinical trial in healthy subjects with no reported adverse events.
The Company has previously reported that in a humanized animal model of lethal Measles infection, NV-387 treatment increased survival of animals to 17 days on average compared to only 7.4 days in untreated animals, an increase of 130%. There were no signs of toxicity from the drug NV-387. Additionally, dose-dependent increase in survival was observed. In contrast, Ribavirin, an unapproved drug that may be used off-label for severe Measles cases as per CDC guidance, is known to be highly toxic.
The Company intends to support any Physician’s Investigator Initiated New Drug Application (IIND) for emergency use of NV-387 for treatment of one or a few cases of Measles, as per FDA regulations. The Company requests physicians that would like to avail of this opportunity to contact us.
NV-387 is a revolutionary novel drug that defines a new mechanism of action, in that it attacks the virus particles and destroys them.
NV-387 is available as Oral Gummies, which dissolve slowly in the mouth; and do not require swallowing. Swallowing can be difficult for a patient in presence of a rash.
With Measles outbreaks spreading all across the country, the USA is expected to lose the Measles elimination status, and the virus would be considered endemic thereafter as it was before 2000. However, Measles is extremely contagious, and more than 95% population needs to be vaccinated to eliminate the disease. To complicate the matters, persons with weakened or otherwise affected immune systems do not benefit from vaccination because their immune system cannot mount response to the challenge.
Further, it has become clear in recent years that the Measles virus is drifting from the current vaccine strain (circa 1968) over the last fifty years, and there is evidence that some variants may have arisen that have greater resistance to the vaccine than in the past.
Thus a drug for combating this emerging infectious disease is important. Regulatory development of a drug specific for Measles is not cost-effective.
NV-387 can be readily developed for Measles through FDA licensure, because it is a multi-purpose, broad-spectrum antiviral. NV-387 is being developed to treat several different viral infections acquired by the respiratory route. The Company is working on regulatory development of NV-387 as a treatment for viral infections that include RSV, Influenza, Bird Flu H5N1, Coronaviruses, COVID-19, the epidemic-threat MPox and the bio-terrorism threat, Smallpox.
Dr. Diwan has been President and Chairman of the Board of the Company since its founding in 2005 Dr. Diwan spearheaded the efforts for the Company’s 2013 uplisting from the OTC Markets to NYSE-American. Dr. Diwan has led several of the Company’s financing efforts since 2010.
Dr. Diwan invented novel polymeric micelle-based nanomedicine technologies as early as 1991. Dr. Diwan is a prolific inventor and a serial entrepreneur. Prior to co-founding NanoViricides, Inc., he has founded TheraCour Pharma, Inc., a privately held company focused in nanomedicines and cell-targeted drug delivery, and AllExcel, Inc., a company with diverse portfolios including nanomedicines, small chemicals, device technologies, as well as informatics. He has won several NIH SBIR (small business innovation research) grant awards. Anil holds a Ph.D. from Rice University, TX, a B.Tech. from Indian Institute of Technology, Mumbai (IIT-B), India, and has consistently held high scholastic ranks and honors. Dr. Diwan has over 25 years of Bio-Pharmaceutical R&D experience with over 20 years as an entrepreneur.
He has several patents issued internationally resulting from three fundamental international patent applications. Under Dr. Diwan’s leadership, NanoViricides, Inc. has been able to keep both administrative and R&D costs at extremely low levels while robustly expanding the drug pipeline every year. Dr. Anil R. Diwan was recognized as “Researcher of the Year” by BusinessNewHaven, a Connecticut Area Business Journal, in 2014.
Ms. Meeta R. Vyas, MBA (Fin.), BS (Chem. Eng.)
interim Chief Financial Officer
Ms. Vyas is known as a strong leader with board level experience and successful achievements as a Senior Executive in a broad range of entities including publicly listed corporations, non-revenue generating entities, and medium to large size companies. Meeta has over twenty-five years of experience in performance and process improvement of both publicly listed companies and non-revenue producing entities, in areas ranging from Finance and Operations to Strategy and Management. Meeta holds the distinction of being the first Indian woman to be named CEO of a publicly listed US corporation, Signature Brands, Inc., best known for “Mr. Coffee” and “Health-O-Meter” brand products. As CEO, acting COO and Vice Chairman of the Board of Signature Brands, Inc., she was responsible for the development and implementation of a turnaround plan, resulting in a return to profitability and growth within a short period of time. Later, as the CEO of the World-Wide Fund for Nature – India (WWF-India) and then as a Vice President of the National Audubon Society (USA), both non-revenue generating entities, Meeta successfully raised unrestricted funding that significantly exceeded annual requirements and also instituted financial processes to measure a variety of performance metrics. Earlier in her career, she was responsible for designing the strategy and initiating the implementation plan for the highly successful information technology outsourcing program at General Electric (GE). Also at GE, Ms. Vyas ran GE Appliances’ Range Products business unit having revenues exceeding $1 Billion where her team doubled operating income in less than two years. Prior to that, as a management consultant with McKinsey and Company, she served publicly listed companies in chemicals, industrial, and technology markets, primarily focusing on growth strategies, valuations, post-merger integrations, and logistics operations. Meeta is married to NanoViricides, Inc. President and Chairman Anil R. Diwan.
Ms. Vyas holds a MBA in Finance from Columbia University’s Graduate School of Business, and a BS in Chemical Engineering from the Massachusetts Institute of Technology.
NanoViricides won the IAIR AWARD as Best North American Company for Leadership in the Nanomedicine Sector.
Randall W. Barton, PhD.
Chief Scientific Officer – Consulting
Dr. Barton has experience in drug discovery and development of both small molecule and biological drug candidates in virology, immunology, inflammation, and cardiovascular diseases in the pharmaceutical and biotech industry as well as academic research and teaching experience. Most recently, he was Vice-President of Drug Discovery at A&G Pharmaceuticals, a biologics and diagnostics company. He retired at the Director level after 20 years at Boehringer Ingelheim Pharmaceuticals. During his time at Boehringer Ingelheim he performed drug development pre-clinical studies on nevirapine (Viramune), a non-nucleoside inhibitor of HIV reverse transcriptase and an important HIV drug.
Prior to joining Boehringer Ingelheim, he was on the faculty at the University of Connecticut Medical School where he was the recipient of an NIH Career Development Award conducting research and teaching in immunology. Dr. Barton has authored over 80 scientific publications, and has been the principal investigator leading to 5 patents. He has a Ph.D. in biochemistry from the University of Tennessee at Oak Ridge National Laboratory and a B.A. from Indiana University.
Jayant Tatake, PhD.
Vice President, R&D
Jay Tatake is an organic chemist with over 25 years of experience in Research and Process Development of fine chemicals. His experience encompasses production scale-up, and large scale manufacture of raw materials for pharmaceuticals. Before joining NanoViricides, Inc., he was Assistant Director of Analytical R&D at Interpharm, Inc. Prior to that, he was Director of Analytical Services at Pharmax Group, Inc. Dr. Tatake has several years experience in Analytical methods development and Quality Control in cGMP environment. His experience includes bio-analytical methods development. Prior to Pharmax Group, he was in the Pharmacology Department, University of Connecticut Health Center, where he synthesized and developed novel bio-conjugates for bio-diagnostics applications.
Jay has a Ph.D. from Department of Chemical Technology, University of Bombay. He is a member of American Chemical Society (ACS). He has published several papers in leading journals and is a co-inventor of several patents.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY INTERACTIVE OFFERS LLC FOR A ONE DAY NNVC AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
The hysteria around crypto in 2025 can best be described as a heady mix of renewed optimism, institutional rush, political symbolism, and speculative excess — all wrapped up in market mania. After years of waiting on the sidelines, many investors interpreted regulatory clarifications and mainstream financial-infrastructure moves as confirmation that digital assets were entering a new era of legitimacy.
For example, the total crypto market cap surged past $4 trillion on the back of industry-friendly laws.
We have seen countless companies follow the trend of building massive crypto treasuries as a hedge and a sign of strength as crypto enters a new era of adoption.
Enter FGNX.
FGNX is on the Ethereum Standard, and singularly focused on becoming the largest corporate holder of ETH in the world by an order of magnitude. In order to enhance our ETH YIELD, the Company will stake and intends to implement other yield strategies while serving as a strategic gateway into Ethereum-powered finance, including tokenized RWAs and stablecoin yield.
We have seen this strategy pay off for several Fortune 500 Companies including Microstrategy (MSTR) who started stockpiling BTC back in 2020.
FGNX’s ETH holdings are hovering just under $210 Million as I type this but we all know crypto is very fluid.
5 Major Catalysts
Dedicated Ethereum Accumulation Strategy: The company emphasizes accumulating ETH (Ethereum) as a core reserve asset rather than holding static crypto exposure.
On-Chain Yield Generation via Staking: ETH holdings are staked and restaked to generate staking rewards, offering an additional layer beyond ETH price movement.
Tokenization & Real-World Asset (RWA) Infrastructure: The company describes plans for bridging real-world assets through tokenization as part of its on-chain finance ecosystem.
Corporate Actions Supporting Structural Flexibilityg: Recent governance and corporate structure changes (increase in authorized shares, name change, charter amendments) indicate adjustments to enable strategic initiatives.
Large-Scale ETH Holdings: As of mid-September 2025, total ETH holdings rose to 49,715 ETH, reflecting accumulation activity and staking yields.
____
FGNX maintains that Ethereum is “the most productive reserve asset of the digital economy,” citing its ability to generate native staking yield, support stablecoins, power tokenized assets, and serve as settlement infrastructure for programmable applications.
FG Nexus operates across multiple functional areas including merchant banking, asset management, reinsurance, and real-world asset tokenization. This multi-pronged approach is designed to interface traditional capital market structures with blockchain-based assets.
Recent Corporate Developments & Capital Structure
⇨Several corporate actions have recently taken place to align the company’s structure to its strategic goals. The name was changed from Fundamental Global Inc. to FG Nexus Inc., and its charter amended to increase authorized shares substantially.
⇨A share repurchase program of up to $200 million has been approved by the Board, offering the company the flexibility to acquire common stock under various conditions.
⇨Also, shareholder approval was recently obtained for increasing authorized shares to 1 trillion, comprising both common and preferred stock. This is presented as enabling maximum flexibility for executing its Ethereum accumulation and capital markets-related strategy.
FG Nexus Initiates $200 Million Share Buyback Program
Charlotte, NC, Oct. 20, 2025 (GLOBE NEWSWIRE) — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company” or “FG Nexus”) today announced that it plans to initiate its previously announced Board-approved $200 million share repurchase program and is entering into an agreement with ThinkEquity to immediately begin buyback purchases. The Company will seek to purchase shares for less than Net Asset Value per share, which is currently estimated to be approximately $5.10 per share as of October 20, 2025.
“If the market is going to give us the opportunity to buy our own shares at a discount to our ETH value per share, we are going to take that opportunity and buy ETH at a discount. Buying back stock at current levels is not only accretive to our net asset value per share, it’s the right thing to do for shareholders. The initiation of our Share Repurchase Program reflects our confidence in FG Nexus’ ETH treasury strategy and our dedication to delivering long-term shareholder value,” said Kyle Cerminara, CEO of FG Nexus. “By purchasing below our Net Asset Value, we are taking immediate action to capitalize on what we believe represents an attractive opportunity.”
ThinkEquity will make its rule 10b-18 purchases (as defined in Rule 10b-18 of the Securities Exchange Act of 1934) in accordance with the following parameters- up to 25% of the daily trading volume while the stock trades below $5.00 per share.
The timing and amount of repurchases under the Share Repurchase Program will depend on a variety of factors, including market conditions, the Company’s financial performance, and other investment opportunities. The Company is under no obligation to repurchase any specific number of shares, and the Share Repurchase Program may be suspended, modified, or discontinued at any time.
FG Nexus affirms that it has will not utilize its At-the-Market (“ATM”) facility while trading below NAV, as doing so would be dilutive on an ETH per share basis. If market conditions change, however, the Company reserves the right to utilize the ATM facility in an accretive manner for the benefit of the stockholders.
Provides Maximum Flexibility to Execute Ethereum Strategy
CHARLOTTE, N.C., Sept. 16, 2025 /PRNewswire/ — FG Nexus (Nasdaq: FGNX, FGNXP) (the “Company”), today announced that a majority of its shareholders have approved by written consent a landmark increase in authorized shares to 1 trillion shares, consisting of 900 billion common shares and 100 billion preferred shares, representing what we believe to be one of if not the largest share authorizations of any U.S. publicly traded company. The increase in authorized shares is not yet effective, but is expected to become effective no earlier than 20 calendar days after the information statement relating to the written consent and related matters is first mailed or otherwise delivered to the Company’s stockholders, and upon the filing of a certificate of amendment with the Secretary of State of Nevada.
“This unprecedented number of authorized shares positions FG Nexus with the most flexible capital structure in the U.S. public markets,” said Kyle Cerminara, Co-Founder, Chairman & CEO of FG Nexus. “Our goal is clear: to systematically acquire ETH in a manner that directly increases ETH per share value for our shareholders while establishing FG Nexus as the dominant institutional holder of Ethereum globally.”
The increase in authorized shares provides FG Nexus with maximum flexibility to execute its strategic vision of becoming the largest corporate holder of ETH in the world by an order of magnitude. By leveraging the authorization and the potential strategic issuance of new shares, FG Nexus will have the unparalleled ability to adapt to future market opportunities and growth initiatives to support the Company’s singular focus on rapidly increasing its Ethereum holdings.
“This historic authorization reflects our shareholders’ confidence in our Ethereum-focused strategy,” said Maja Vujinovic, CEO of Digital Assets at FG Nexus. “As we continue building long-term ETH per share growth and reinforcing our conviction that Ethereum is the backbone of tomorrow’s financial system, this authorization ensures we have the capital structure tools necessary to maximize long-term shareholder value.”
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY VIRTUS MEDIA GROUP LLC FOR A ONE DAY FGNX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Operations in 20+ countries, with commercial relationships spanning 600+ of the world’s largest telecom operators
Now a Debt-Free Nasdaq Company With No Convertible Notes or Warrants and Plans to Give $500,000 in Shares as Dividend by the End of the Year
IQST – IQSTEL and Cycurion Enter a New Era of AI-Cybersecurity, Completing Phase One of Their Next-Generation Cyber Defense Rollout (Just Announced)
Forecasting $400 million in revenue for FY-2025, reinforcing its trajectory toward becoming a $1 billion tech-driven enterprise by 2027.
Hello Everyone,
We have something back on our radar that we need you to research out ahead of Wednesday’s session. We have taken a look at this a few times. When it was brand new to the market we brought it you out ahead of a 65% overnight jump on a squeeze. IQST may be in a similar situation right now down here hovering around $6. This one doesn’t even have a year under it’s belt on the Nasdaq after the up-list but it is sitting just above the lows of 5.60.
They are a multinational technology company offering cutting-edge solutions in Fintech, Blockchain, Artificial Intelligence (AI), and Cybersecurity. Telecom, High-Tech Telecom Services (eSIM, roaming, cloud), with over 600 global business relationships. With operations in 21 countries and a team of 100 employees, IQSTEL serves a broad global customer base with high-value, high-margin services.
In 2024, IQSTEL reported $283 million in revenue, yet their market cap remained at only about 10% of that figure. They also achieved 96% year-over-year revenue growth but valuation has not kept pace with performance, leaving plenty of room for growth for IQST. This year the company is forecasting $400M right now after they bumped it up following huge revenues in the Summer.
• Strong and Expanding Telecom Operations
iQSTEL delivers international wholesale voice and SMS services to more than 35 top-tier telecom providers—including Verizon, Vodafone, and China Mobile—as well as hundreds of secondary carriers. Through interconnections with over 600 partners across more than 20 countries, the company has built a robust and far-reaching global network. Over the past year, iQSTEL’s voice traffic rose by 24%, while SMS volumes increased 23%, reflecting strong customer satisfaction and sustained growth in demand.
• A Relationship-Centered Approach to a Relationship-Driven Industry
In global telecommunications, success depends on trust, experience, and access. iQSTEL’s leadership team leverages deep-rooted relationships cultivated over decades to maintain a significant competitive edge. CEO Leandro Iglesias and his executives have transformed long-standing personal and professional connections into enduring commercial partnerships and favorable interconnection agreements that underpin the company’s expansion.
• Asset-Light Model Drives High Efficiency and Returns
Instead of investing in costly infrastructure, iQSTEL leases network capacity from a market abundant in telecom bandwidth. This capital-efficient, asset-light strategy allows the company to achieve stronger returns, maintain flexibility, and rapidly scale or adapt to new opportunities as they emerge.
• Strategic and Disciplined M&A Execution
Since going public in 2018, iQSTEL has successfully completed nine acquisitions—each sourced through the management team’s established industry network. Every acquired company’s CEO was personally known to Mr. Iglesias prior to acquisition. Post-merger, these leaders typically remain onboard under earn-out structures, ensuring smooth integration and continuity of customer relationships. iQSTEL’s model of acquiring a 51% controlling interest balances capital efficiency with operational control.
• Rapid Revenue Growth and Path to Profitability
iQSTEL’s revenue surged 96% last year, reaching $283 million, and the company is approaching positive EBITDA territory. Management expects to achieve a $400 million annualized revenue run rate by year-end, aided by a recent acquisition anticipated to contribute roughly $85 million in yearly revenue. The long-term target is $1 billion in revenue—positioning iQSTEL among established peers like IDT (NYSE: IDT) and Cogent (NASDAQ: CCOI).
• Compelling Valuation with Meaningful Upside
Comparable telecom firms currently trade at an average EV/EBITDA multiple of 9.2x for 2026 estimates, while close peers such as IDT and Cogent command roughly a 15% premium. Headquartered in Miami, iQSTEL operates under a distinctive asset-light model originally developed by its founder—formerly the head of CANTV’s international business—who launched Etelix in 2008. Following its 2018 public listing through a reverse merger, the company has pursued a steady stream of acquisitions fueling rapid top-line expansion. This year, iQSTEL is optimizing integration by consolidating traffic flows to its lowest-cost routing subsidiaries through global interconnection agreements and migrating operations onto a unified technology platform with its vendor partner.
The company has Four Key Competitive Advantages:
• Exceptional Industry Relationships – CEO Leandro Iglesias brings 27 years of telecom experience, including leadership at CANTV—formerly Venezuela’s top-tier national carrier and once partly owned by Verizon and Telefónica. His personal network spans the globe and includes current executives at many of the world’s largest carriers.
• Strategic Customer Acquisition – Management has leveraged its relationships to secure over 35 major international telecom customers and hundreds of tier 2 customers. These are high-volume, recurring relationships that drive consistent growth and reduce churn risk.
• Buyer Advantage in Oversupplied Market – Management also utilizes the same connections to secure the lowest-cost routing and termination agreements with global telecom carriers. Telecom is an opaque industry, and personal connections are important in negotiating favorable terms. The company benefits because the telecom industry has overbuilt, deploying too many network assets, so negotiations favor buyers like iQSTEL.
• Proven Acquisition Strategy – Every acquisition the company has completed has been of a company founded and run by an entrepreneur that Mr. Iglesias has known personally for many years. His modus operandi is to acquire an initial 51% stake, keep management on board, and give them earn-outs for continuing to perform after the acquisition.
iQSTEL is the Combination of Nine Acquisitions
Acquisitions are a key to the company’s growth strategy. To date, it has completed nine acquisitions to get the company to its present state of five operating voice telecom subsidiaries, two operating SMS subsidiaries, two fintech subsidiaries, and one metaverse joint venture.
Consideration paid for the eleven acquisitions has totaled $17.57 million, including the reverse merger of the CEO’s original business into a shell company. By comparison, the company has a roughly $30 million market cap, only owns 51% stakes in six business units and a 75% stake in one, with 100% stakes in only the original Etelix and QGlobal SMS acquired in 2020. To bring its stake up to 100% in each of its business units would require an estimated $11.3 million at the original purchase prices; however, much of this is expected to be paid in shares.
The founders have been known professionally to the CEO for several years and are willing to stay on and run the business with earnouts for performance. Keeping the founders in place is important because they have personal relationships with the customers.
Key Drivers
IQSTEL (NASDAQ: IQST) continues to deliver strong performance and expand its footprint as a Global Connectivity, AI & Digital Corporation:
Diversified Growth – Four strategic business lines: Telecommunications, Fintech, Artificial Intelligence, and Cybersecurity.
Global Reach – Operations in 20+ countries, with commercial relationships spanning 600+ of the world’s largest telecom operators.
High-Margin Expansion – A powerful platform to layer in additional services, including AI, fintech, and cybersecurity solutions — highlighted by our partnership with Cycurion.
IQSTEL Intelligence Momentum – Our IQSTEL Intelligence division is growing faster than expected. Highlights include the ONAR partnership, the Mobility Tech partnership, the Cycurion alliance, plus three more contracts in the sales funnel, expected to close before year-end.
Strong Financial Trajectory – On track toward $1 billion in revenue by 2027, with a projected $15M EBITDA run rate in 2026.
Institutional Confidence – Approximately 12 institutional investors now hold 4% of IQST shares, just 120 days after our Nasdaq uplisting.
Research Recognition – Litchfield Hills Research issued a detailed report with an $18 price target: https://shre.ink/te9s
Momentum in Q2 & Q3 – $35M revenue in July, surpassing a $400M annual run rate five months ahead of schedule. Assets per share stand at $17.41, outperforming across net equity, gross revenue, margins, net income, and adjusted EBITDA.
Innovation in AI – Launch of www.IQ2Call.ai, targeting the $750B global market with vertical AI-Telecom integration, including next-gen AI for U.S. healthcare call centers.
Fintech Acceleration – Acquisition of Globetopper (July 1, 2025), forecasted to add $34M revenue and positive EBITDA in H2 2025.
Balance Sheet Strength – $6.9M debt reduction (~$2 per share), reinforcing our equity position. Notably, half of this debt was voluntarily converted by investors into Preferred Shares, underscoring their trust in IQSTEL’s vision, management, and growth strategy.
Revenue Mix – Current revenue stream: 80% telecommunications, 20% fintech, with fintech and AI & Digital services set to accelerate growth.
IQST – IQSTEL and Cycurion – CYCU Enter a New Era of AI-Cybersecurity, Completing Phase One of Their Next-Generation Cyber Defense Rollout
Published
Oct 21, 2025 8:45am EDT
IQSTEL’s Reality Border and Cycurion Join Forces to Deliver AI Agents with Built-In Cyber Defense and Proactive Threat Hunting Capabilities — Marking the First Step Toward Building the Industry’s Most Secure AI Ecosystem for Global Telecom and Enterprise Clients
NEW YORK, Oct. 21, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST) today announced that Reality Border, IQSTEL’s AI subsidiary, has completed Phase One of its joint program with Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion”) to deliver a new generation of AI-enhanced cybersecurity. The milestone introduces a secure Model Context Protocol (MCP) integration for Airweb.ai (web AI agent) and IQ2Call.ai (voice AI agent), now fronted and protected by Cycurion’s ARx multi-layer cybersecurity platform.
“Our customers can now deploy AI agents with confidence,” said Leandro Iglesias, President of IQSTEL. “By pairing an MCP layer with Cycurion´s advanced platformARx’s deception-driven, multi-layer inspection, we’re moving from reactive defense to proactive threat hunting at the edge of our AI experiences.”
“ARx was designed for mission-critical environments,” added L. Kevin Kelly, Chairman & CEO of Cycurion. “Integrating with Reality Border’s MCP-enabled agents means threats are intercepted, analyzed, and acted upon before they can touch core assets.”
What Phase One Delivers (now live)
MCP Interface for Airweb & IQ2Call – standardized, secure context/tooling layer for AI-agent workflows operating in detect/protect modes.
ARx Reverse-Proxy Shielding – obscures true server IPs and diverts adversaries to hardened defenses and decoys.
Four-Layer ARx Defense (current config)
Geo-Gating (region-based blocking)
WAF & API Security (request inspection & filtering)
Proprietary Bot Hunter (malicious automation detection while allowing legit bots)
Dynamic Threat Intelligence – real-time 13M+ malicious IP blocklist with continuous updates and automated blocking.
Operational Visibility – dashboards/SIEM integration, packet-level drill-downs, and adaptive rules for rapid action.
Model Context Protocol (MCP), in practice
MCP standardizes how AI agents securely discover, request, and use tools/data from external systems, enforcing auditable permissions and least-privilege policies.
In Phase One, Reality Border uses MCP to:
Normalize AI-Agent Tooling — Airweb.ai and IQ2Call.ai expose capabilities as MCP tools behind ARx (e.g., Knowledge Ops; secure webhooks/email/SMS; IQ2Call call control: initiate/end calls, warm transfers, Dual-Tone Multi-Frequency (DTMF), post-call notes; scheduling/CRM handoffs). All are schema-described to eliminate ad-hoc integrations.
Enforce Policy at the Edge — Every MCP request/response is fronted by ARx (reverse proxy + four-layer defense); malicious sessions are challenged or blocked in real time.
Static defenses struggle against fast-moving, automated adversaries. ARx’s preemptive, deception-driven approach halts threats before impact, while MCP turns Airweb and IQ2Call into well-governed, least-privilege clients of enterprise systems—reducing risk without sacrificing speed.
This is only the beginning. IQSTEL and Cycurion are building a powerful AI-enhanced cybersecurity ecosystem. With IQSTEL’s AI services now protected by Cycurion’s advanced ARx platform, the next phase will go beyond defense — delivering solutions where AI takes the lead in cyber protection, predicting, adapting, and neutralizing threats before they emerge.
About Cycurion Inc.
Based in McLean, Virginia, Cycurion (NASDAQ: CYCU) is a forward-thinking provider of IT cybersecurity solutions and AI, committed to delivering secure, reliable, and innovative services to clients worldwide. Specializing in cybersecurity, program management, and business continuity, Cycurion harnesses its AI-enhanced ARx platform and expert team to empower clients and safeguard their operations. Along with its subsidiaries, Axxum Technologies, Cloudburst Security, and Cycurion Innovation, Inc., Cycurion serves government, healthcare, and corporate clients committed to securing the digital future.
IQST – IQSTEL Becomes a Debt-Free Nasdaq Company With No Convertible Notes or Warrants and Plans to Give $500,000 in Shares as Dividend by the End of the Year
Published
Oct 9, 2025 8:45am EDT
IQSTEL Eliminates All Convertible Notes, Completes Full Payment of QXTEL and Globetopper Acquisitions, and Accelerates Cycurion Partnership
NEW YORK, Oct. 9, 2025 /PRNewswire/ — IQSTEL Inc. (NASDAQ: IQST), a Global Connectivity, AI & Digital Corporation, proudly announces it has eliminated all convertible notes from its balance sheet and fully paid for its most recent acquisitions, QXTEL and Globetopper.
With this achievement, IQSTEL has officially become a debt-free company — with no convertible notes and no warrants outstanding — reinforcing its solid financial foundation and long-term commitment to creating shareholder value.
“This is a defining moment for IQSTEL,” said Leandro Iglesias, CEO of IQSTEL Inc. “We have completely eliminated convertible debt and finalized full payment for our latest acquisitions. IQSTEL is stronger, cleaner, and better positioned than ever to execute our growth strategy and deliver consistent value to shareholders.”
A Strong Balance Sheet and Strategic Flexibility
IQSTEL officially enters the select club of debt-free companies, standing out with $17.41 in assets per share and a clean capital structure with zero convertible debt and no warrants outstanding.
This solid financial foundation gives IQSTEL the strength and flexibility to continue executing its growth strategy, supported by a robust balance sheet that reinforces investor confidence.
Building Shareholder Value: $500,000 Dividend Planned
This milestone is a concrete demonstration of how IQSTEL creates shareholder value — reducing liabilities, increasing tangible assets, and delivering real financial benefits.
In conjunction with this financial progress, IQSTEL plans to distribute a $500,000 dividend in shares before the end of 2025, as part of its strategic partnership with Cycurion.
This dividend underscores IQSTEL’s commitment to rewarding shareholders while executing strategic initiatives that expand high-margin business lines and strengthen long-term value creation.
Accelerating Cycurion Partnership and AI-Driven Cybersecurity
IQSTEL is now accelerating its collaboration with Cycurion, developing and deploying AI-enhanced cybersecurity services for the global telecom and enterprise markets.
Through this partnership, IQSTEL has entered the cybersecurity arena with a trusted U.S. government-certified technology provider, expanding its portfolio of Telecom, Fintech, AI, and Digital services.
“Eliminating debt, paying off acquisitions, delivering dividends, and expanding into high-tech verticals like AI and cybersecurity — this is how IQSTEL continues to build long-term shareholder value,” added Iglesias.
Financial Growth Objectives
IQSTEL’s roadmap remains on track, with a goal to achieve a $15 million EBITDA run rate in 2025 and a $1 billion revenue run rate by 2027, reinforcing its evolution into a Global Connectivity, AI & Digital Corporation.
IQSTEL Launches Investor Landing Page
To enhance transparency and provide easy access to corporate updates, IQSTEL has launched its official Investors Landing Page, a dedicated portal summarizing key financial metrics, strategic milestones, and news updates.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD BY CORPORATE ADS LLC FOR A ONE DAY IQST AWARENESS CAMPAIGN ON WEDNESDAY AND FRIDAY. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Micropolis Expands into Egypt & North Africa with AERXIO
Micropolis and Dubai Police Launch the First Autonomous Patrol Vehicle
Micropolis’ collaboration with NVIDIA embeds the company’s GPU, AI simulation, and Orin edge computing technologies into Micropolis’ autonomous vehicle platforms
We have an action packed week ahead of us with some great companies to take a look at.
This next on is a rising force from Dubai is already putting autonomous patrol robots to work — backed by government contracts and NVIDIA’s cutting-edge AI ecosystem.
Micropolis (NYSE: MCRP), headquartered in the UAE, has begun real-world deployment of AI-powered patrol systems for public safety and infrastructure security. Its integration of NVIDIA’s Orin-based computing and membership in NVIDIA’s Inception and Metropolis programs provide the company access to world-class AI tools and infrastructure — the same that power the leading autonomy players globally.
According to Goldman Sachs, the humanoid robotics market could reach $150 billion annually by 2035, while the broader AI robotics sector may exceed $350 billion by 2030. As governments worldwide accelerate adoption of AI-driven patrol and mobility systems, Micropolis is emerging as a uniquely positioned, publicly traded company ready to capture this growth.
Every industry leader experiences a pivotal moment when innovation, timing, and execution align — and Micropolis appears to be entering that phase.
As a first mover in autonomous mobility and AI robotics within the GCC, Micropolis maintains strong partnerships with public-sector organizations, including Dubai Police, to advance smart city security and infrastructure monitoring.
The company’s solutions address critical operational needs across defense, logistics, urban safety, and environmental management — all sectors undergoing rapid AI-driven transformation across the Gulf region.
Government-led initiatives such as the UAE’s National AI Strategy and Saudi Arabia’s Vision 2030 have created fertile ground for robotics adoption. Micropolis’ partnerships with Dubai Police and SEE Holding’s Sustainable City 2.0 are well aligned with these long-term policy goals.
Since going public in March 2025, Micropolis has accelerated product development, expanded its ecosystem, and deepened relationships with major stakeholders in the Middle East.
With real deployments underway, the company is operating in the shadow of global giants — but not for long.
Micropolis and Dubai Police Launch the First Autonomous Patrol Vehicle
Micropolis and Dubai Police have announced the official deployment of the DPR-02 Autonomous Police Patrol at Dubai Global Village, marking the first operational use of AI-powered patrol vehicles in the Emirate.
The patrol integrates advanced detection, analytics, and fleet management tools designed to enhance surveillance, crowd monitoring, and rapid-response capabilities. This rollout represents a key step forward in Dubai’s strategy to integrate advanced robotics into public safety operations — reinforcing the city’s position as a global leader in smart policing.
Micropolis’ vertically integrated robotics platform — combining mechatronics, embedded systems, and autonomous software — enables Dubai Police to continuously monitor, analyze, and respond to dynamic environments in real time.
The DPR-02 will begin service on October 15, 2025, at Dubai Global Village, supporting Dubai Police operations throughout the year.
AI-Powered Patrol for a Safer Future
The Autonomous Police Patrol is built to enhance surveillance and response capabilities in high-traffic areas, featuring:
AI-driven Detection and Recognition of people, vehicles, and suspicious behaviors.
Behavior Analysis and Suspect Profiling, providing predictive insights based on movement patterns.
Mission Planner and Fleet Management Software, enabling centralized control and coordination.
Powered by Micropolis’ proprietary autonomous software stack, the patrol operates independently while feeding live intelligence to command centers, boosting both efficiency and safety.
Innovation Partnerships
Micropolis designed and built the Autonomous Police Patrol entirely in the UAE, highlighting Dubai Police’s commitment to supporting locally developed, sustainable technology.
“The DPR-02 marks the first official deployment of autonomous patrol technology for Dubai Police,” said Major General Khalid Alrazooqi, CIO of Dubai Police. “This innovation demonstrates how AI can enhance public safety and strengthen smart policing initiatives.”
“Partnering with Dubai Police to bring this vision to life is a proud moment for us,” said Fareed Aljawhari, Founder and CEO of Micropolis. “This collaboration showcases how UAE innovation can redefine intelligent mobility and urban safety.”
Micropolis Expands into Egypt & North Africa
In August 2025, Micropolis announced an exclusive distribution agreement with AERXIO FZ-LLC, granting AERXIO sole rights to distribute Micropolis’ unmanned ground vehicles and AI technologies across Egypt and North Africa.
AERXIO’s strong network across the region will accelerate Micropolis’ international growth strategy — bringing its autonomous patrol systems, AI platforms, and robotics solutions to new, high-demand markets.
“This partnership creates opportunities to address critical security challenges in border and infrastructure protection,” said Fareed Aljawhari.
The agreement includes distribution of Micropolis’ flagship platform, The Patrol, built for open-road and desert operations, featuring 15-hour runtime, rapid charging, and onboard Microspot AI analytics for law enforcement.
A Massive $350Bn Sector
Unlike competitors still testing prototypes, Micropolis is already deployed in the field — with Dubai Police, Emirates Steel, and leading smart city developers.
Amid the GCC’s growing AI investments (projected to add $320Bn to regional GDP by 2030, per PwC), Micropolis stands out as a pure-play AI infrastructure company with real traction and scalable technology.
This is the phase where early positioning can matter most — before large-scale contracts and mass deployment bring greater market attention.
Product Lineup
M-Platform
The foundation of Micropolis’ robotics ecosystem, the M-Platform features modular mobility systems adaptable for various applications, from security to logistics. With drive-by-wire systems, smart power distribution, and centralized AI control, it offers durability and flexibility across terrains.
M-Patrol
Developed with Dubai Police, the M01 and M02 Patrol Units address distinct urban and open-road environments, equipped with 360° AI vision, autonomous navigation, and behavior analysis tools.
Microspot
Micropolis’ proprietary AI surveillance and analytics engine, Microspot delivers real-time facial and object recognition via edge computing — enhancing safety, response, and situational awareness for public and defense applications.
Major Catalysts
Strong Market Momentum: The AI and robotics landscape across the GCC is expanding rapidly, with PwC projecting that artificial intelligence alone could contribute $320 billion to the Middle East’s GDP by 2030. Key growth sectors — including public safety (18.6%), logistics (15.2%), and manufacturing (12.4%) — align directly with Micropolis’ strategic focus areas, positioning the company at the heart of this regional transformation.
Technological Edge: Through extensive in-house R&D and advanced production capabilities such as additive manufacturing and precision 3D printing, Micropolis delivers customized, high-performance solutions tailored to client needs. Its proprietary systems — including the M01 and M02 patrol platforms, Micropolis Robotic Control Unit (MRCU), and Smart Power Distribution Unit (SPDU) — provide a strong technological advantage in reliability, scalability, and autonomous operation.
Strategic Regional Footprint: National programs like the UAE’s AI Strategy and Saudi Vision 2030 are driving adoption of robotics and smart infrastructure across the Gulf. Initiatives such as the Mohamed bin Zayed University of Artificial Intelligence and the Saudi Data and AI Authority further support an innovation-focused ecosystem — one in which Micropolis is uniquely positioned to thrive.
Partnerships Driving Scale: Collaborations with Dubai Police, Emirates Steel, and other major entities demonstrate Micropolis’ ability to secure long-term, institutional partnerships. Ongoing market expansion efforts — including entry into new territories — are expected to create multiple revenue streams, while the company’s commitment to bespoke system customization ensures adaptability across industries.
Deep Integration with NVIDIA: Micropolis’ collaboration with NVIDIA embeds the company’s GPU, AI simulation, and Orin edge computing technologies into Micropolis’ autonomous vehicle platforms. This integration enhances real-time perception, decision-making, and navigation directly on the robot, eliminating reliance on cloud processing and delivering faster, safer, and more efficient performance.
Exclusive North Africa Expansion with AERXIO FZ-LLC: Under an exclusive distribution agreement with AERXIO FZ-LLC, a UAE-based technology provider, Micropolis has granted AERXIO sole rights to market and distribute its unmanned ground security vehicles throughout Egypt and North Africa. This partnership significantly broadens Micropolis’ geographic reach and accelerates its presence in new, high-demand markets across the African continent.
Micropolis Launches Final Phase of Autonomous Police Patrol Pilot with Dubai Expo City, Dubai Police, and Transguard Group
DUBAI, United Arab Emirates, Aug. 04, 2025 (GLOBE NEWSWIRE) — Micropolis Holding Co. (“Micropolis” or the “Company”) (NYSE: MCRP), a pioneer in unmanned ground vehicles and AI-driven security solutions, today announced it has commenced the final phase of its flagship pilot project in collaboration with Dubai Expo City, Dubai Police, and Transguard Group.
This milestone represents a significant advancement in the evolution of Micropolis’s M2 Autonomous Police Patrol, which will undergo extensive testing and validation across its full operational suite. The project will focus on real-world performance evaluation of the enhanced autonomous driving system, the mission planner, tele-operator control functions, and the newly developed radio communication protocol.
In parallel, Micropolis and its partners will conduct rigorous testing of the integrated AI models designed for facial recognition, suspect tracking, and behavior analysis, which are critical capabilities for enhancing urban safety and law enforcement efficiency.
As part of its proprietary technology suite, Micropolis will also deploy and validate its in-house developed edge computing units, built on the AJX NVIDIA Orin platform. These advanced units will be installed on the autonomous patrol vehicles and strategically positioned CCTV cameras, providing enhanced on-site processing capabilities and enabling faster decision-making at the network edge.
The final testing phase is scheduled to commence in mid-August 2025 and continue through the end of September 2025, establishing the foundation for broader deployment of the M2 platform in public safety and smart city initiatives.
“This final phase of the pilot represents a pivotal moment for autonomous policing technology,” said Fareed Aljawhari, Founder & CEO of Micropolis. “Years of rigorous development and strategic partnerships have brought us to this critical juncture where we can demonstrate the M2 platform’s transformative potential for urban security and public safety operations.”
This project reinforces Micropolis’s commitment to pioneering advanced robotics and AI technologies that are tailored to meet the complex demands of modern urban environments.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY PRIMETIME PROFILES LLC FOR A ONE DAY MCRP AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Some of the company’s high-potential mineral rights are adjacent to or near large lithium deposits that belong to a large, publicly traded comparable that boasts a $1.2 Billion market cap!
Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries
Atlas Lithium Subsidiary’s Iron Quadrangle Project on Track for Q4 2025 Revenues
Atlas Lithium’s Subsidiary Reports Outstanding Rare Earth Mineralization Across Two Project Types
Atlas Critical Minerals (OTCQB: JUPGF) reports high-grade, near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂; achieves 96.6%… pic.twitter.com/9Wzc7A4u2i
— Atlas Lithium (Nasdaq: ATLX) (@Atlas_Lithium) July 24, 2025
_________________________
Hello Everyone,
We want you to take another look at ATLX.
You should be familiar with this one.
We looked at it a month ago when it was around 4.50. Last week it hit 8.25, so I would say it has been performing well since. Before you pull the calculator out thats a 83% move.
We even just saw their partly owned subsidiary, Atlas Critical Minerals explode from under .75 to 3.93 in under a month for a massive 425% move.
Since ATLX hit those highs it has pulled back slightly under 6 right now.
Focused on moving from exploration to profitability; Atlas Lithium Corporation (NASDAQ: ATLX) is a U.S.-based mineral exploration company with the largest size and breadth of exploration projects for strategic minerals in Brazil, a premier mineral jurisdiction.
ATLX intends to be a leader in the provisioning of minerals essential to the transformation of the global economy from fossil fuels to electrification, a process which is expected to take decades.
The company’s properties encompass approximately 539 km2 for lithium, as well as mineral rights for nickel, rare earths, titanium and graphite. Atlas Lithium also owns 32% of Atlas Critical Minerals Corporation.
Over the last several years, Atlas Lithium has assembled Brazil’s largest portfolio of lithium mineral rights among publicly listed companies.
ATLX holds three key projects that span the major lithium-mineralized zones in LV:
The Neves Project in southern LV, Atlas Lithium’s flagship development, which has recently been permitted and is advancing towards production;
The Salinas Project in northern LV, spanning 2,070 acres with natural spodumene outcrops, and is located 4.7 miles from Latin Resources Ltd., and with potential for spodumene deposits;
The Clear Project in central LV, which encompasses 470 acres, is situated 3.8 miles from Sigma Lithium’s (NASDAQ: SGML) Grota do Cirilo mine. There is also potential for spodumene deposits. Sigma Lithium has a market cap of roughly $1.2B! (Note: ATLX’s lithium processing manager James Schloffer had a key role at Sigma!)
Atlas Lithium’s Subsidiary Reports Outstanding Rare Earth Mineralization Across Two Project Types
Atlas Critical Minerals Reports Strong Results from Dual Deposit Strategy Covering Both Ionic Clay and Conglomerate-Hosted Rare Earth Systems
Boca Raton, Florida–(Newsfile Corp. – September 22, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or “Company”), a leading lithium development company, is pleased to announce that its subsidiary Atlas Critical Minerals Corporation (“ACM”) (OTCQB: JUPGF) has reported excellent results from its diversified rare earth portfolio strategy, establishing Brazil’s most comprehensive rare earths project portfolio.
In particular, ACM has successfully demonstrated the potential viability of two distinct rare earth deposit types through its recent technical studies for the Iporá Project (in Goiás State) and Alto do Paranaíba Project (in Minas Gerais State), creating a compelling diversified strategy that provides multiple pathways to production across different deposit characteristics.
Key Highlights of Diversified Rare Earth Portfolio
Iporá Ionic Clay Project Highlights:
High-grade drilling intercepts including 8 meters at 2,071 ppm TREO (Total Rare Earths Oxide) with 775 ppm MREO (Magnetic Rare Earths Oxide) in drillhole DHIP-0006
Strong metallurgical results with MREO recovery rates exceeding 60% for critical permanent magnet elements
HREO (Heavy Rare Earth Oxides) recovery rates of 55% and Yttrium recovery rates of 63%
Alto do Paranaíba Project Highlights:
Near-surface mineralization featuring grades up to 28,870 ppm TREO and 23.2% TiO₂
Consistent high-grade mineralization across all three exploration blocks
Strong correlation between rare earth elements and titanium mineralization
The diversified approach provides ACM with reduced geological risk through multiple deposit styles, varied metallurgical processing approaches offering different cost structures and recovery rates, and enhanced optionality for development sequencing. Ionic clay deposits typically offer simpler processing with lower capital requirements, while conglomerate-hosted deposits can provide larger-scale resources.
“Our strategic stake in Atlas Critical Minerals provides shareholders with exposure to the broader critical minerals sector and strengthens Atlas Lithium’s position within global supply chains for materials vital to energy transition and national security,” said Marc Fogassa, Chief Executive Officer and Chairman of Atlas Lithium. “The outstanding results from both the ionic clay and conglomerate-hosted rare earth systems demonstrate the exceptional geological potential of our subsidiary’s Brazilian portfolio.”
Strategic Location Advantages
Both projects benefit from their strategic positioning in Brazil’s established mining regions. The Iporá Project is located in Goiás State, home to Serra Verde, one of the only integrated rare earths mining and processing operations outside of Asia. The Alto do Paranaíba Project enjoys robust infrastructure including power, water, and roads, positioning both assets for potential development.
Atlas Critical Minerals now controls over 218,000 hectares of critical mineral rights in Brazil, encompassing projects in rare earths, titanium, graphite, and uranium – minerals essential for defense applications, electrification, and energy security.
Atlas Lithium Subsidiary’s Iron Quadrangle Project on Track for Q4 2025 Revenues
Strategic Partnership Model Allows for Near-Term Cash Flow Generation
Boca Raton, Florida–(Newsfile Corp. – September 2, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or “Company”), a leading lithium development company advancing towards production at its flagship Neves Lithium Project, today announced significant progress by its 30%-owned subsidiary, Atlas Critical Minerals Corporation (OTCQB: JUPGF) (“Atlas Critical Minerals” or “ACM”). ACM’s Iron Quadrangle Project is expected to generate initial revenues in the fourth quarter of 2025 through a strategic partnership with an iron ore processing company, marking a major milestone in the Company’s diversified portfolio strategy.
The Iron Quadrangle Project, named after its world-renowned location in the State of Minas Gerais, Brazil, will leverage a capital-efficient revenue model through partnership with an established iron ore processor. Under this arrangement, mining operations and processing of extracted iron ore will be performed by the partner company, which owns processing facilities capable of transforming ACM’s unprocessed iron ore into high-quality sinter feed. Atlas Critical Minerals will receive revenues from its run-of-mine material and a percentage of the final sinter feed product sales. Figure 1 is a photograph of the plant expected to process ACM’s iron ore.
“This development represents a significant step forward for our portfolio of quality projects with reasonable timeline to production,” said Marc Fogassa, Chairman and CEO of Atlas Lithium Corporation. “Our ownership stake in Atlas Critical Minerals is expected to provide our shareholders with exposure to multiple minerals and their uncorrelated revenue streams. The Iron Quadrangle Project’s path to near-term profitability exemplifies this strategy.”
The Iron Quadrangle Project benefited from ACM’s systematic exploration and development. Atlas Critical Minerals acquired the mineral right in 2020, conducted detailed geological exploration including a drilling campaign covering approximately 10% of the area in 2021 and 2022, and published an initial technical report in accordance with U.S. guidelines in 2022. The Iron Quadrangle Project received a 10-year operational license from the State of Minas Gerais in May 2024 and its mineral right was granted mining concession status by the Ministry of Mines and Energy in May 2025.
Atlas Lithium’s Neves Project Completes Definitive Feasibility Study Estimating 145% IRR and 11-Month Payback
Boca Raton, Florida–(Newsfile Corp. – August 4, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or “Company”), a leading lithium development company, is pleased to announce that SGS Canada Inc. (“SGS”) has completed the Definitive Feasibility Study (“DFS”) for the Company’s 100%-owned Neves Lithium Project (“Project”), a technical report prepared under the U.S. guidelines of Item 1300 of Regulation S-K (“Regulation S-K 1300”). This hard-rock Project is well-suited to being a low-cost open-pit mining operation, as its spodumene deposits are located relatively close to the surface. Located in the state of Minas Gerais, Brazil, the Project encompasses 4 of the 98 mineral rights for lithium owned by Atlas Lithium. As detailed in the DFS, the Neves Project is expected to deliver strong financial metrics with an internal rate of return (“IRR”) of 145%, payback in 11 months from the start of operations, and an after-tax net present value (“NPV”) of $539 million. Importantly, the DFS estimates the Neves Project to have operational production costs of only $489 per tonne of lithium concentrate, positioning Atlas Lithium among the world’s lowest-cost producers. Complete details of these metrics can be found in the DFS, filed with the Securities and Exchange Commission as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. Marc-Antoine Laporte from SGS serves as the Qualified Person for the DFS under Regulation S-K 1300. SGS is well-known as a global leader in testing, inspection, and certification services for mineral properties and projects.
Industry-Leading Capital Efficiency and Low Operating Costs
The DFS supports that expected direct capital expenditures of $57.6 million will be needed for the implementation of the Project, by far the lowest such capital costs among other announced projects in Brazil. Notably, Atlas Lithium has already invested approximately $30 million in acquiring and transporting the Project’s newly fabricated dense media separation (“DMS”) plant to Brazil, as previously reported. The Company has secured two non-dilutive pre-payment agreements for its lithium concentrate totaling $40 million and has received additional funding interest from other parties, including 10-year debt financing options, any of which could support the Project’s capital requirements.
The Company believes that the DFS validates the Project’s strong economics, positioning it among the most capital-efficient and lowest-cost hard-rock lithium developments globally. The Project will employ proven DMS technology, with comprehensive metallurgical testing demonstrating an expected robust lithium recovery rate of 61.7% to produce high-quality, low-impurity lithium concentrate. This relatively straightforward, low-risk DMS processing methodology minimizes technical complexity and operational risk while enabling a low environmental footprint.
Atlas Lithium’s mineral right to be mined, as detailed in the DFS, received its “Portaria de Lavra” (mining concession) status from Brazil’s Ministry of Mines and Energy on May 27, 2025 — the highest level of titleship in Brazil and one that allows continuous mining operations. Multiple deposit areas within the Project remain open for resource expansion along strike and at depth and are thus expected to extend the life of mine. Additionally, numerous high-potential geological targets remain within the Project’s mineral rights, providing compelling opportunities for future exploration.
Located in the established Araçuaí Pegmatite District in the Vale do Jequitinhonha, often called Lithium Valley, the Project benefits from favorable infrastructure, including proximity to transportation networks, water resources, and skilled labor. The Project qualifies for tax incentives from the Superintendency for the Development of the Northeast (SUDENE), as promulgated by Brazil’s Ministry of Integration and Regional Development, reducing the corporate tax rate from 34% to 15.25% and further enhancing profitability.
“The DFS indicates potentially outstanding returns for our initial vision of developing a focused, near-term, profitable lithium production asset with minimal capital requirements,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “The combination of our low capital intensity and rapid payback period is expected to create exceptional value for our shareholders while positioning Atlas Lithium to benefit from future organic expansion opportunities at Neves and other high-potential lithium areas that we own. Importantly, we are creating many quality employment opportunities in the Vale do Jequitinhonha region, representing a significant societal contribution of our Project.”
Following his leadership role in collaborating with SGS on the DFS, project implementation activities are being supervised by Eduardo Queiroz, Atlas Lithium’s Project Management Officer (PMO) and Vice President of Engineering. Mr. Queiroz has more than two decades of hands-on experience managing complex, large-scale mining projects.
“The DFS demonstrates the technical robustness of the Project, with proven DMS technology and comprehensive metallurgical test work validated by SGS, a premier firm in the lithium space,” said Mr. Queiroz. “With our processing plant fully fabricated and paid for, and now with the DFS in hand, we have systematically de-risked the Project. I am excited to lead the implementation phase of Atlas Lithium’s journey to becoming a lithium producer.”
Salinas and Clear: The Next Expansion Frontier
Atlas Lithium is strategically positioned to capitalize on its extensive regional lithium exploration portfolio in Brazil, particularly through advancement of its Salinas Project and Clear Project, both 100% owned by the Company. Atlas Lithium’s Salinas Project is just 5 miles east of the Colina lithium asset previously owned by Latin Resources — a major factor in Pilbara Minerals’s acquisition of that company in 2024 for approximately $370 million. At the Salinas Project, Atlas Lithium has already achieved promising initial results, including the discovery of spodumene-rich pegmatites very close to the surface, and highly positive results from soil geochemistry and from LIDAR geological mapping.
Atlas Lithium’s Clear Project is located less than 4 miles from Sigma Lithium’s operating lithium mine, and represents significant untapped potential with highly positive results from soil geochemistry and from LIDAR geological mapping.
Diversification in Critical Minerals
Atlas Lithium also owns approximately 30% of Atlas Critical Minerals Corporation (OTCQB: JUPGF), a separate company with exploration programs in uranium, rare earths, titanium, and graphite.
Atlas Critical Minerals reports high-grade, near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂; achieves 96.6% graphite concentrate
Boca Raton, Florida–(Newsfile Corp. – July 24, 2025) – Atlas Lithium Corporation (NASDAQ: ATLX) (“Atlas Lithium” or the “Company”), a leading lithium exploration and development company, today announced strong results from its 30.1%-owned subsidiary, Atlas Critical Minerals Corporation (OTCQB: JUPGF). The subsidiary has recently reported near-surface rare earths mineralization with grades up to 28,870 ppm TREO, 23.2% TiO₂, alongside graphite concentrate results of up to 96.6%. Atlas Critical Minerals owns over 575,000+ acres of mineral rights for rare earths, titanium, graphite, uranium, copper, and nickel. Brazil, where the subsidiary operates, hosts significant rare earth deposits and holds the world’s second-largest graphite reserves.
Alto Paranaíba Rare Earths and Titanium Project Demonstrates High Potential
Atlas Critical Minerals’ Alto Paranaíba rare earths and titanium project in Minas Gerais, located in a proven rare earths region, is divided into three exploration blocks for operational efficiency as shown in Figure 1.
Atlas Critical Minerals’ 770 surface samples yielded consistently attractive grades, including a sample with 28,870 ppm total rare earth oxides (TREO) and another containing 23.2% titanium dioxide (TiO₂). Highlight sampling results from Block 3 South are presented in Figure 2.
Atlas Critical Minerals’ Minas Gerais graphite project achieved strong metallurgical test results, with conventional flotation techniques producing graphite concentrates grading up to 96.6% total graphite carbon. Exploration samples showed graphite carbon grades up to 15.42%.
Strategic Importance
The strategic importance of securing robust critical minerals supply chains was recently underscored by the U.S. Department of Defense’s $400 million investment in MP Materials, making it the largest shareholder in the U.S. rare earth miner.
Atlas Lithium’s strategic stake in Atlas Critical Minerals provides shareholders with direct exposure to the broader critical minerals sector and strengthens the Company’s position within global supply chains for materials vital to energy transition and national security.
“Our focus remains on advancing our flagship Neves lithium project toward production, while our significant stake in Atlas Critical Minerals allows our shareholders to also benefit from exposure to a broader range of critical minerals at a time of heightened geopolitical importance,” said Marc Fogassa, Chief Executive Officer and Chairman of Atlas Lithium. “The initial results from Atlas Critical Minerals’ rare earths, titanium, and graphite programs are highly encouraging and underscore the strong potential of these assets.”
Atlas Lithium’s Modular Processing Plant Arrives in Brazil, Achieving Critical Milestone Toward Production
Boca Raton, Florida–(Newsfile Corp. – March 10, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium development company, announces the successful arrival of its modular Dense Media Separation (DMS) lithium processing plant at the Port of Santos, Brazil. This pivotal achievement underscores the Company’s progress toward becoming a key lithium producer in Brazil’s emerging Lithium Valley.
The components of Atlas Lithium’s lithium processing plant were carried by the cargo vessel Irene’s Wisdom (IMO: 9953391) which arrived at the Port of Santos on March 7, 2025, delivering 141 containers and 10 bulk components. Fully owned and paid for by Atlas Lithium, this newly manufactured facility departed from the Port of Durban, South Africa, on February 2, 2025, following months of careful planning and preparation. Two additional containers, containing spare parts, are scheduled to arrive in the near future.
“This marks a transformative milestone for Atlas Lithium as we advance toward becoming a global supplier in the lithium market,” said Marc Fogassa, Chairman and CEO of Atlas Lithium. “With operational permits secured and our modern lithium processing facility now in Brazil, we have overcome two of the most significant hurdles on our journey to production.”
Cutting-Edge Modular Plant Design
Atlas Lithium’s lithium processing plant incorporates advanced design elements and sustainable technology that set a new benchmark for lithium processing:
Compact, Modular Design: Allows streamlined transportation, installation, and commissioning, reducing time to production.
Reduced Environmental Footprint: Optimized physical layout minimizes environmental impact while maintaining high operational efficiency.
Advanced Water Conservation: Internal recycling systems with lower water consumption compared to traditional plants.
Sustainable Tailings Management: Dry-stacking technology eliminates the need for tailings dams, promoting greater environmental sustainability.
Strategic Progress Toward Production
The Neves Project, Atlas Lithium’s flagship operation, received its operational permit from the state of Minas Gerais in October 2024. The project is positioned to initially produce up to 150,000 tonnes per year of battery-grade spodumene concentrate, a critical raw material for lithium-ion batteries.
Atlas Lithium’s operations will benefit from Brazil’s Lithium Valley’s strategic advantages, including expected lower production costs as compared to suppliers from Australia and other regions.
Atlas Lithium Strengthens Position in Critical Minerals with Rare Earths, Titanium, Graphite, and Uranium Exposure
Boca Raton, Florida–(Newsfile Corp. – March 5, 2025) – Atlas Lithium Corporation(NASDAQ: ATLX), a leading lithium exploration and development company, is pleased to highlight its current 32.2% stake in Atlas Critical Minerals Corporation. This ownership positions Atlas Lithium at the forefront of Brazil’s critical minerals sector, providing exposure to rare earth elements, titanium, graphite, uranium, and other sought-after minerals.
“Global demand for critical minerals has never been more urgent,” said Marc Fogassa, CEO and Chairman of Atlas Lithium. “Recent geopolitical developments have underscored the vital importance of critical minerals for economic and national security. Atlas Lithium is strategically positioned to play a key role in this increasingly important sector.”
Rare Earths: Essential for Defense, Energy, and High-Tech Applications
Rare earth elements are indispensable components in manufacturing permanent magnets used in electric vehicle (EV) motors, wind turbines, and defense systems. With Chinacurrently controlling over 60% of global rare earth mining and 85% of refining capacity, recent export restrictions have underscored the need for alternative supply sources.
Atlas Critical Minerals’ extensive rare earth portfolio spans approximately 54,000 hectares (~133,000 acres) across 33 mineral rights in the states of Goiás and Minas Gerais in Brazil. These areas have demonstrated promising mineralization, with soil samples revealing rare earth oxide (TREO) concentrations as high as 15,000 ppm and titanium dioxide concentrations up to 20%.
Graphite: A Cornerstone of Battery Technology
Graphite is a critical component for lithium-ion batteries, which power electric vehicles and renewable energy storage systems. As global EV adoption accelerates, demand for natural graphite has surged, making the development of new sources outside of traditional suppliers like China a strategic imperative. Atlas Critical Minerals is actively evaluating areas in Brazil with known graphite formations, with the goal of contributing to the global supply of this essential material.
Uranium: Fueling the Energy Transition
Uranium is experiencing renewed global demand as nations prioritize energy security, geopolitical stability, and decarbonization. With nuclear power offering a reliable, low-carbon energy source, uranium has become integral to the energy transition. Atlas Critical Minerals is focused in certain areas in Brazil with promising geological characteristics for uranium. In Brazil, uranium is strictly regulated and exploration requires special permitting, which is not guaranteed. Nevertheless, this sector is expected to continue to grow substantially as Brazil activates its third nuclear reactor for electricity generation and as global demand continues to rise.
A Diversified Strategy for a Changing World
Atlas Lithium’s ownership stake in Atlas Critical Minerals strategically complements its flagship Neves Project in Brazil’s Lithium Valley. This diversified approach provides shareholders with exposure to multiple critical minerals essential for the global energy transition and advanced manufacturing sectors.
“In today’s environment of persistent geopolitical tensions, the need for reliable, diversified critical mineral supply chains has never been clearer,” added Fogassa. “While our immediate focus is to bring our lithium production online and generate profits, Atlas Lithium’s long-term strategy is to establish itself as a leader in the global critical minerals space.”
Strategic Partnership with Global Industrial Giant
In a transformative development, Atlas Lithium secured a strategic partnership with Mitsui & Co., Ltd., one of Japan’s largest global trading and investment companies with operations in over 60 countries. In March 2024, Mitsui demonstrated its confidence in Atlas Lithium’s potential by making a substantial US$30 million strategic investment at a 10% premium to market price. The partnership includes a significant offtake agreement lithium concentrate from Atlas Lithium’s Neves Project. Notably, Mitsui’s largest shareholder is Warren Buffett’s Berkshire Hathaway, adding another layer of institutional validation to Atlas Lithium’s business model.
Within the global lithium industry, Brazil’s LV has emerged as a premier hard-rock lithium jurisdiction.
Brazil’s advantages include year-round mining operations, lower labor costs, and a supportive government. The country’s lithium industry outperforms Australian producers on costs; Pilbara Mineral’s US$370M acquisition of a Brazilian lithium explorer in August 2024 highlights the region’s importance.
“Investments in lithium production in Minas Gerais are projected to range from $3.9 billion to $5.8 billion by 2030,” according to João Paulo Braga, CEO of the state investment promotion agency, Invest Minas.
Few countries besides Brazil have such an advantageous position to attract investment, as other Latin American nations face uncertainties and political risks.
ATLX’s Minas Gerais Lithium Project is its largest endeavor and consists of 85 mineral rights totaling approximately 468 km2 which include seven main clusters of prospective mineralization: Neves (currently being explored by drilling campaign and referred to as the “Neves Project”), Coronel Murta, Eastern Properties, Itinga, Salinas, Santa Clara, and Tesouras.
Several of the company’s mineral rights are located adjacent to or near mineral rights that belong to a large publicly traded competitor company which has demonstrated through extensive drilling the presence of lithium deposits totaling over 100 million tons, according to its publicly available filings!
This is a Highly Attractive Location:
◼ Resource Potential to Support Large Scale Operations ✓ The Brazilian Geological Service (CPRM) suggested that the region has at least 45 lithium deposits ✓ Adjacent to operational lithium mines in the region such as Sigma Lithium and CBL
◼ Licensing Fast Track to Speed up Project Execution – Atlas with Permits in Place ✓ Minas Gerais government created a fast-track process, under the InvestMinas Program, to facilitate project development and allow for licensing to be issued quickly ✓ Mining friendly jurisdiction: 300+ operating mines in the state of Minas Gerais
◼ Favorable Infrastructure ✓ Access to abundant renewable & clean energy sources and highway roads directly connected to intercontinental ports to supply main markets
Recent exploration activities at both the company’s Salinas and the Clear Projects have yielded significant progress, and such development bodes well for ATLX’s strategy of securing as many high-quality deposit areas within LV as feasible.
A Big Neighbor
Atlas Lithium’s strategic holdings of 85 mineral rights across 468 km2 in Minas Gerais position it as the emerging force in Brazil’s Lithium Valley, with several properties adjacent to Sigma Lithium Corporation, the region’s established producer. Sigma’s current market capitalization of approximately $1.2 billion—approximately twelve times that of Atlas Lithium—demonstrates the extraordinary value potential in the region. As Atlas Lithium follows a similar development path in the same proven lithium district the company represents a compelling growth opportunity at its current market valuation. The success of Sigma Lithium in establishing large-scale lithium operations provides a clear blueprint for Atlas Lithium’s development trajectory in this world-class mining jurisdiction.
Marc Fogassa has been a director and our Chairman and Chief Executive Officer since 2012. He has extensive experience in venture capital and public company chief executive management. He has served on boards of directors of multiple private companies in various industries and has been invited to speak about investment issues, particularly as related to Brazil. Mr. Fogassa double majored at the Massachusetts Institute of Technology (M.I.T.), graduating with two Bachelor of Science degrees in 1990. He later graduated from the Harvard Medical School with a Doctor of Medicine degree in 1995 and also from the Harvard Business School with a Master of Business Administration degree in 1999 with Second-Year Honors. At Harvard Business School, he was Co-President of the Venture Capital and Private Equity Club. Mr. Fogassa was born in Brazil and is fluent in Portuguese and English. Mr. Fogassa is also the Chairman and Chief Executive Officer of Jupiter Gold Corporation and Chairman and Chief Executive Officer of Apollo Resources Corporation, two companies in which we own equity positions.
Tiago Miranda
CFO & Treasurer
Tiago Miranda is our Chief Financial Officer, Principal Accounting Officer, and Treasurer. From February 2024 until July 2024, Mr. Miranda was the Chief Financial Officer of Apollo Resources Corporation, a private company and a subsidiary of Atlas Lithium. In such capacity, Mr. Miranda managed all of Apollo Resources’ financial and administrative related processes, including treasury, accounting, tax, and financial planning and budgeting.
Previously, from May 2020 to December 2023, Mr. Miranda was the senior financial officer for the Brazilian operations of Horizonte Minerals Plc., a British publicly listed company with two nickel projects in Brazil. During his tenure, he successfully contributed to securing project financing of US$713 million for a ferronickel project and an additional $300 million Brazilian real credit facility with Banco da Amazônia. Between November 2019 to April 2020, Mr. Miranda held the position of Financial Controller for the Brazilian operations at Equinox Gold, a Canadian publicly listed gold producer.
From March 2008 to October 2019, Mr. Miranda served as the Controller of Ferrous Resources Ltd., an iron producer partially owned by Icahn Enterprises, a NYSE-listed company. He actively contributed to the development of company projects from exploration through construction and operation and was also heavily involved in Ferrous Resources’ US$550 million sale to Vale S/A, the largest Brazilian mining company.
From September 2005 to March 2008, Mr. Miranda was an auditor with Deloitte Touche Tohmatsu in Brazil. He has an undergraduate degree in Business Administration and Accounting, and a Master of Business Administration, both from IBMEC in Brazil. Mr. Miranda is fluent in Portuguese and English.
Eduardo Queiroz
Project Management Officer (PMO) & Vice President of Engineering
Eduardo Queiroz has served as Project Management Officer and Vice President of Engineering at Atlas Lithium since December 2024. He brings over 20 years of expertise in managing large-scale and complex mining projects, most recently as General Manager of Planning and Management at Bamin, a unit of Eurasian Resources Group. During his tenure at Bamin, he successfully led the strategic planning of several projects exceeding US$3 billion in value, including an integrated iron ore mining project that encompassed mining operations, processing plant, railway, and ocean port facilities.
Mr. Queiroz’s comprehensive experience includes engineering oversight, environmental compliance, risk management, and the implementation of cost-efficient operational strategies. His expertise in project implementation and management of Brazilian mining projects makes him instrumental in driving Atlas Lithium’s Neves Project toward revenue generation. He holds an MBA in Project Management from Fundação Getúlio Vargas and a degree in Civil Engineering from the Universidade Federal de Ouro Preto.
Igor Tkachenko
Vice President, Corporate Strategy
Igor Tkachenko has been our Vice President of Corporate Strategy since 2023. Igor Tkachenko, a Ukrainian-American and a US-trained physician, has served as a strategic advisor to us since 2021, lending his leadership talents and private sector experience to further the company’s mission to become a leading hard-rock lithium provider for the green energy transition. In 2022, Mr. Tkachenko began consulting for us as our Director of Strategic Development, overseeing the rapid expansion of our investor relations efforts. He participated in the design and execution of our organizational growth strategy that led to our successful up-listing to Nasdaq in January 2023. On the heels of this major milestone, Mr. Tkachenko transitioned from his academic role as a Clinical Assistant Professor to take on an executive position at Atlas Lithium and began serving as our Vice President of Corporate Strategy in 2023. His education includes a Bachelor of Science (Summa Cum Laude) and a Doctor of Medicine degrees.
SINCERELY,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY SIDEWAYS FREQUENCY LLC FOR A ONE DAY ATLX AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Management expects approximately $4 million in revenue for Q3 2025, reflecting the first full quarter of operations with Resource Group
Safe and Green Development Corporation Achieves Strategic Milestone with Acquisition of Resource Group —- On a pro forma basis, the combined entity is projecting ~$25 million in annualized revenue for 2025
__________________________________
Hello Everyone,
We wanted to put something brand new on your radar ahead of Wednesday’s session.
This is our very first look at this one. The company has a strong back story and the company is quickly putting itself on the map as they start to put some strong numbers up after a recent major acquisition.
Pull up SGD right away.
Safe & Green Development Corporation (NASDAQ: SGD) isn’t the same company it was a year ago. What began as a small, overlooked developer has rapidly transformed into a vertically integrated environmental and real-estate enterprise, one that’s now posting explosive growth, restructuring for efficiency, and capturing attention in the small-cap market.
SGD’s story now blends two powerful sectors: real estate development and the green-economy infrastructure boom. Its composting and engineered-soils operations align with growing state-level mandates for organic waste recycling and carbon-reduction goals, while its property portfolio offers built-in asset value.
With triple-digit growth, tangible assets, and operational diversification, Safe & Green Development Corporation has quietly evolved from a microcap curiosity into a company with legitimate long-term potential.
From Dormant to Dominant: A 3,200% Revenue Surge
The headline numbers speak volumes. In its most recent quarter, SGD reported over $1.4 million in revenue, up a staggering 3,200% year-over-year, compared with just $42,000 in the same quarter a year prior.
That growth was driven by SGD’s acquisition of Resource Group US Holdings LLC (RGUS) a thriving operator in the organics, composting, and logistics sectors. The integration immediately gave SGD a recurring-revenue business model and a clear path toward scale.
Management has already indicated expectations for roughly $4 million in Q3 2025 revenue, marking the first full quarter with RGUS fully consolidated. On a pro forma basis, the combined entity is projecting ~$25 million in annualized revenue for 2025.
The Resource Group Acquisition: Real Assets, Real Operations
Unlike many small-cap pivots that rely on speculative promises, SGD’s acquisition of RGUS added tangible operations and infrastructure. The deal brought in:
A fully permitted composting facility
Two green-waste aggregation sites
A transportation fleet for organics and environmental materials
An experienced management team and operating staff
According to unaudited 2024 figures, RGUS generated $18.75 million in revenue and $9.4 million in gross profit, while trimming its net loss to under $1 million — down from $6.2 million the prior year.
These are real numbers from a real business, now sitting inside SGD’s corporate structure.
Real Estate: A Hidden Value Layer
SGD hasn’t abandoned its roots. Its development arm remains a valuable source of optionality and capital. The company holds multiple parcels of land, including sites in Lago Vista, Texas and Durant, Oklahoma, collectively appraised at approximately $9.9 million.
In recent months, SGD:
Sold its St. Mary’s property for $1.4 million
Entered a contract to sell Lago Vista for $6.575 million
Closed 22 lots in a South Texas joint-venture project
These transactions inject liquidity and demonstrate that SGD’s real-estate portfolio isn’t just sitting on the books, it’s active, monetizeable, and capable of funding future expansion.
Cleaning House: Strategic Resets Paying Off
While SGD posted a GAAP net loss of $5.72 million in Q2 2025, most of that was due to one-time items — including impairment charges and bad-debt write-offs tied to legacy operations.
The adjusted EBITDA loss was just $634,000, reflecting a company still investing heavily in growth but beginning to normalize its cost structure.
SGD also restructured its board of directors, adding three new members from RGUS to ensure operational continuity and accountability. The integration of management across both sides has been deliberate — and it’s beginning to show in the financials.
Why This Turnaround Looks Different and what separates SGD from the rest:
Actual operating business: The acquisition brought immediate revenue and tangible assets.
Vertical integration: SGD now owns the full cycle — collection, processing, and distribution, giving it control over margins.
Real estate leverage: The company can unlock liquidity through land sales or development while scaling its environmental arm.
Aligned incentives: RGUS shareholders received stock and board seats, ensuring both sides benefit from long-term success.
In short: this is no longer a speculative “pivot” it’s a genuine transformation with evidence in the numbers.
Safe and Green Development Announces Strategic Plan to Unlock Shareholder Value Post-Acquisition
MIAMI, June 11, 2025 /PRNewswire/ — Safe and Green Development Corporation (NASDAQ: SGD) announces that its wholly owned subsidiary, Resource Group US Holdings LLC (“Resource”) is expanding into being able to produce high-value potting media and soil substrates through the implementation of advanced milling technology.
By leveraging Resource’s exclusive license to utilize cutting-edge Microtec milling technology, patented German-engineered systems with over 90 global installations, Resource expects to move beyond commodity compost and expand into higher-value markets. The company is introducing a suite of sustainable, potentially high-margin soil products under its “Renewable Earth™” brand. By converting woody and vegetative waste into finely milled potting media and substrates, Resource may be able to access a market where product pricing can reach approximately $150 per ton, potentially up to five times the value of traditional compost offerings. A preview of the expected Renewable Earth product packaging can be seen in the image accompanying this release.
“This product represents a potential fundamental revaluation of organic waste as a resource,” said Tony Cialone, CEO of Resource Group. “We’re not just managing green waste we’re engineering premium, sustainable products that reduce reliance on environmentally harmful peat and imported coir while creating circular economic value.”
“As we integrate Resource’s proven logistics, proprietary processing capabilities, and deep regional market knowledge, we intend to unlock a scalable, environmentally responsible business model with attractive margins and robust growth potential,” said David Villarreal, CEO of Safe and Green Development Corporation. “We believe Resource is positioned to lead the next generation of sustainable soil solutions supporting the horticulture, agriculture, and consumer landscaping sectors with products designed for performance, sustainability, and impact,”
The Company expects to finalize the delivery and installation of the Microtec mill in the third quarter.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY PRIMETIME PROFILES LLC FOR A ONE DAY SGD AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
There are many analysts saying the Blue Chips are overbought right now, that is why we are seeing so much interest in the small cap markets. There have been some siginifcant movers as of late that have turned some heads. Over the last month we have seen double digit moves become commonplace. Now we don’t know how long that will last or even what companies will be on the move over the next month, but once you dive into ADUR and analyze the move on the chart down below there we are sure that you are going to want to take a deep dive into this company and check out what is moving the needle here.
Aduro Clean Technologies is a developer of patented water-based technologies to chemically recycle waste plastics; convert heavy crude and bitumen into lighter, more valuable oil; and transform renewable oils into higher-value fuels or renewable chemicals. The Company’s Hydrochemolytic™ technology relies on water as a critical agent in a chemistry platform that operates at relatively low temperatures and cost, a game-changing approach that converts low-value feedstocks into resources for the 21st century.The company trades in America, Canada & Germany.
After their uplisting in late 2024 from OTC Markets to Nasdaq, ADUR traded sideways for a 5 or so months as we often see. Since the beginning of April ADUR has been on a complete rampage. This chart cannot be over looked. ADUR has been decimating resistance and keeps making 52 week highs consistently over the past 5 months. How often do you see a chart like this?
Aduro Makes Major Strides Toward Commercialization
It’s been a big stretch for Aduro as the company continues to move its Hydrochemolytic™ Technology (HCT) from the lab toward commercial-scale reality. Over the past few months, Aduro has been busy forming partnerships, expanding leadership, and advancing construction of its much-anticipated NGP Pilot Plant.
First up, Aduro signed an MOU with NexGen Polymers to explore building a demonstration-scale HCT plant. Together, they’ll evaluate feedstock sources, potential sites, and operational design — all aimed at generating the kind of real-world data needed to move HCT closer to commercial deployment. NexGen’s deep experience in polymer processing makes them an ideal collaborator for scaling up this tech.
Aduro also partnered with Siemens Canada, bringing in their expertise in automation and process control for the NGP Pilot Plant. With Siemens on board, the plant will have top-tier safety systems, data capture, and industrial reliability built in from day one.
In another move, Aduro signed an MOU with Cleanfarms, a Canadian organization specializing in agricultural waste recovery. The two will test HCT’s ability to process difficult-to-recycle farm plastics like silage film, bale wrap, and grain bags — materials that typically end up in landfills. This project will help determine if HCT can become a viable solution for agricultural plastics.
To back all this with data, Aduro engaged Delphi, a Canadian sustainability consultancy, to perform a Life Cycle Assessment of HCT. The study will measure environmental impacts such as greenhouse gas emissions and energy efficiency compared to traditional recycling methods, ensuring transparent, third-party validation.
Meanwhile, construction of the NGP Pilot Plant is progressing rapidly with Zeton. Major site upgrades are complete, key equipment has passed testing, and Siemens’ automation systems are being integrated. Commissioning is set to begin this fall, with phased testing through October to ensure a safe and efficient start-up.
Financially, Aduro strengthened its position with a successful U.S. public offering in June, raising about US$9.2 million. The added capital will help fund continued R&D and scale-up efforts.
On the leadership front, Aduro named David Weizenbach as Chief Operating Officer. With decades of experience at NOVA Chemicals and other industrial leaders, he’ll guide the company through pilot-scale execution and operational readiness.
Aduro also deepened its industry engagement, joining the Plastics Industry Association (PLASTICS) and the Polystyrene Recycling Alliance (PSRA) — groups driving innovation in recycling and circular economy initiatives. This ties directly into Aduro’s early work on converting polystyrene into valuable hydrocarbons using its HCT process.
And finally, the company completed successful tests on synthetic turf waste, demonstrating that HCT can process this complex mix of materials into useful hydrocarbons — even with contaminants present. The results have already sparked interest from major industry stakeholders looking for new ways to handle turf and composite waste.
All told, Aduro is clearly hitting its stride — combining strategic partnerships, financial strength, and real progress in the field to bring HCT closer to commercial reality.
Aduro Advances on All Fronts — Partnerships, Progress, and Pilot Plant Momentum (More Accomplishments Since IPO)
Aduro is accelerating its push toward commercialization with a series of key partnerships, technical milestones, and organizational growth initiatives that are setting the stage for the company’s next chapter.
Partnering with NexGen Polymers Aduro recently signed a Memorandum of Understanding (MOU) with NexGen Polymers to explore the development of a demonstration-scale HCT plant. Together, the two companies will evaluate feedstock supply, site options, and plant operations to optimize data collection and refine commercial-scale solutions. NexGen’s expertise in polymer processing and materials management makes it an ideal collaborator as Aduro moves closer to real-world deployment of its Hydrochemolytic™ Technology.
Collaboration with Siemens Canada To ensure best-in-class automation and process safety, Aduro also formed a strategic collaboration with Siemens Canada. Siemens will provide advanced control systems, automation solutions, and engineering support for the NGP Pilot Plant, helping to ensure the plant operates efficiently, safely, and with reliable data collection from day one.
Tackling Agricultural Plastics with Cleanfarms Another new partnership came through an MOU with Cleanfarms Inc., a Canadian organization focused on agricultural waste recovery. Together, Aduro and Cleanfarms will test the potential of HCT to recycle hard-to-handle farm plastics such as silage film, bale wrap, and grain bags — materials that often end up in landfills. The goal: to determine both the technical and economic feasibility of recycling these plastics using Aduro’s process.
Independent Environmental Review with Delphi To provide transparency around its environmental impact, Aduro engaged Delphi, a Canadian sustainability consultancy, to conduct an independent Life Cycle Assessment (LCA) of its HCT technology. The study will measure greenhouse gas emissions, energy use, and efficiency compared to traditional recycling methods — giving customers, regulators, and investors third-party validation of HCT’s sustainability potential.
NGP Pilot Plant Nears Commissioning Construction of the NGP Pilot Plant is moving full steam ahead with engineering partner Zeton. Site upgrades are complete, key components have passed factory testing, and Siemens’ automation systems are being integrated. Commissioning is scheduled to begin in September 2025, with full integration and initial operations expected to follow in October. The multi-phase start-up will ensure the plant meets the highest standards of safety and reliability.
Leadership Expansion Aduro also announced the appointment of David Weizenbach, P.Eng., as Chief Operating Officer. With over 30 years of experience at major industrial companies like NOVA Chemicals, Weizenbach brings deep expertise in automation, safety, and capital project execution — right as Aduro transitions from R&D to operational scale-up.
Industry Engagement The company joined the Plastics Industry Association (PLASTICS) and the Polystyrene Recycling Alliance (PSRA), connecting Aduro to a network of industry leaders focused on advancing circular economy initiatives. Aduro’s early work converting polystyrene into valuable hydrocarbon intermediates aligns directly with PSRA’s goals and highlights the versatility of HCT in tackling difficult-to-recycle plastics.
Feedstock Innovation – Synthetic Turf Success Lastly, Aduro announced promising test results on synthetic turf waste — a notoriously complex material used in sports and landscaping. Using HCT, Aduro successfully converted the polyolefin components of turf into shorter-chain hydrocarbons without extensive preprocessing. This breakthrough demonstrates HCT’s ability to handle mixed and contaminated materials and opens up new recycling opportunities for synthetic turf, an emerging global waste challenge.
The bottom line is that you need to research ADUR immediately. Charts like this don’t happen by accident. Take a good look at the company and regardless make sure it is on your screen in the premarket.
September was all about progress. Long-lead equipment arrived, installation began, and commissioning of the #PilotPlant is underway—an important milestone as we move closer to demonstrating our Hydrochemolytic™ Technology at pilot scale. $ADUR#CleanTech#EcoInnovationpic.twitter.com/d94L8yARbi
— Aduro Clean Technologies (@AduroCleanTech) October 7, 2025
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF TWENTY THOUSAND USD BY LFG EQUITIES CORP FOR A ONE DAY ADUR AWARENESS CAMPAIGN. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
Health In Tech and AlphaTON Capital Sign Strategic Letter of Intent to Develop HITChain
Total revenues in 2nd quarter were $9.3 million, up 86% YoY, while first-half year revenues were $17.3 million
The company currently operates in 41 states, serving 942 business clients, 24,839 enrolled employees, and 778 brokers and TPAs
__________________________________
Hello Everyone,
We want you to turn your attention to Health in Tech (Nasdaq: HIT) ahead of Wednesday’s session.
If not, it might be worth taking a look — the company has been getting a lot more attention lately, and for good reason.
HIlT went public back in December. For a while, the stock didn’t do much, trading sideways before it took a big tumble in March, dropping well below the $1 mark. That selloff seemed to clear out the early IPO traders and short-term holders.
Since June, though, the story has completely flipped. The stock has staged an impressive comeback — climbing steadily, breaking through resistance levels, and showing some serious staying power.
On Tuesday HIT hit $3.81, its highest point since those rough days in March. That kind of recovery doesn’t happen by accident. The stock closed up about 12% on Monday, with trading volume that more than doubled its recent average — a sign that more investors are starting to pay attention.
The rally really kicked off around June 18th, and over the following month the stock tripled, logging only four red days in that span. Clearly, this isn’t the same HIT that debuted on the Nasdaq in late 2024.
What sparked the turnaround? A string of strong announcements — starting with solid earnings. HIT reported $9.3 million in revenue, up 86% year-over-year, and $17.3 million in revenue for the first half of the year — nearly matching all of 2024’s total in just six months. The company also reported over $8 million in cash on hand.
HIT operates an Insurtech platform that integrates third-party AI technology to streamline and automate processes across the healthcare insurance space. The platform helps insurance companies, brokers, and TPAs simplify underwriting, sales, and service workflows — cutting out friction and inefficiencies.
For context, self-funded health plans let employers pay healthcare claims directly, with stop-loss coverage for major expenses. HIT’s proprietary tech supports this model by simplifying complex underwriting and increasing transparency across the system.
While giants like UnitedHealth still dominate U.S. healthcare, smaller AI-driven companies like HIT are beginning to carve out meaningful space. The company currently operates in 41 states, serving 942 business clients, 24,839 enrolled employees, and 778 brokers and TPAs.
Several major news releases have followed since those earnings — helping fuel the momentum that’s pushed HIT sharply higher over the past few months.
A week later they announced a major expansion of its Enhanced Do-It-Yourself Benefit System (eDIYBS), extending its fast, AI-driven underwriting platform from small employers to mid- and large-sized businesses. The upgrade allows brokers serving companies with 150 or more employees to instantly upload and process claims data in multiple formats, dramatically cutting quoting times from months to about 10–14 days. Previously, eDIYBS reduced small-group quotes from two weeks to just minutes. The system’s new features include seamless data uploads, automated compliance checks, and a redesigned interface that reduces manual work and errors. With this expansion, HIT is entering the larger, higher-value employer market—positioning itself as a unified, technology-driven exchange for healthcare insurance at scale.
First, Health In Tech (Nasdaq: HIT) announced a strategic Letter of Intent with AlphaTON Capital (Nasdaq: ATON) to co-develop HITChain, a blockchain-powered healthcare claims processing platform built on The Open Network (TON). The partnership aims to tackle one of the biggest inefficiencies in U.S. healthcare—claims processing costs, fraud, and delays—by creating a transparent, verifiable system that reduces administrative expenses and improves trust among insurers, providers, and employers. Combining Health In Tech’s insurance expertise with AlphaTON’s blockchain and cybersecurity capabilities, HITChain seeks to modernize a $300+ billion segment of the $4.5 trillion U.S. healthcare market. The initiative positions HIT at the forefront of decentralized healthcare infrastructure and digital innovation in insurance technology.
Health In Tech Announces Second Quarter 2025 Financial Results
Revenues of $9.3 million, up 86% YoY; The first-half year revenues of $17.3 million, 89% of full year 2024.
Adjusted EBITDA of $1.6 million, up 134% YoY; The first-half year adjusted EBITDA of $2.8 million, 1.2 times full year 2024.
Cash balance of $8.1 million.
STUART, Fla. , July 21, 2025 /PRNewswire/ — Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced its financial results for the second quarter ended June 30, 2025.
Financial Highlights for the Second Quarter and First-Half of 2025:
Revenues. Total revenues were $9.3 million, up 86% YoY. The first-half year revenues of $17.3 million, 89% of FY2024 total.
Billed Enrolled Employees. The number of billed enrolled employees (EEs) was 24,839, an increase of 5,738 EEs YoY.
Distribution. The number of Brokers, Third-party Administrator (“TPAs”) and Agencies expanded to 778 partners, up 87% YoY.
Pre-tax income. Pre-tax income was $0.8 million, more than doubled YoY; The first-half year pre-tax income of $1.5 million, 1.7x of FY2024.
Adjusted EBITDA. Adjusted EBITDA was $1.6 million, up 134% YoY; The first-half year adjusted EBITDA of $2.8 million, 1.2x of FY2024.
Cash. Cash balance was $8.1 million as of June 30, 2025.
Accounts receivable, net. Accounts receivable balance was $1.3 million as of June 30, 2025, reduced $0.2 million YoY.
“We delivered another strong quarter of profitable growth, with total revenue reaching $9.3 million—up 86% year over year—and first-half revenues already at 89% of our full-year 2024 total,” said Tim Johnson, CEO of Health In Tech. “Our distribution network has expanded to 778 partners—an 87% increase year over year—reflecting our strategic focus on growing beyond traditional broker channels. We’ve established partnerships with TPAs offering technology-driven solutions, regional healthcare benefit providers, and service platforms that support small businesses. This approach is broadening our market reach and delivering greater value to our customers. The 30% increase in billed enrolled employees and strong adoption across our network underscore the demand for our differentiated services and offering.”
Mr. Johnson added, “What’s particularly exciting is that many of our partners are now using our platform to bundle healthcare insurance with their existing services, enabling them to serve small business employer better by offering integrated, end-to-end solutions. Our AI-powered platform is easy to implement and highly intuitive, making it an ideal tool for partners seeking efficiency and scalability. With a broader distribution footprint and multiple new relationships in place, we’re confident in our ability to maintain strong growth momentum through the rest of the year.”
“We’re pleased with our second quarter results, which reflect strong execution and disciplined financial management across the business,” said Julia Qian, CFO of Health In Tech. “Q2 revenue reached $9.3 million, bringing first-half revenue to $17.3 million—already 89% of our full-year 2024 total—driven by continued strategic expansion of our distribution network and strong customer acquisition. Adjusted EBITDA for the quarter was $1.6 million, up 134% year over year, with first-half adjusted EBITDA reaching $2.8 million—1.2 times our full-year 2024 result. First-half pretax income represented 8.8% of revenue, a nearly 300 basis point improvement year over year, demonstrating our ability to maintain expense discipline and allocate resources effectively to drive top-line growth. Supported by a solid $8.1 million cash position, we remain focused on investing in high-impact initiatives and advanced technology solutions that scale efficiently and sustain profitable growth.”.
Recent Business Developments and Highlights
Verdegard Administrators: an integrated, concierge-level TPA, owned by MedImpact, the largest independent pharmacy benefit manager (PBM) in the U.S., managing prescription benefits for over 20 million members and processing tens of billions in annual drug transactions. This partnership will enable us to reduce costs for small businesses.
Unified Health Plans: a premier TPA recognized for its extensive provider network across Kansas. It has extensive provider network and focuses on controlling cost drivers and improving care quality. Unified dominates several niche business sectors in Kansas. The partnership with HIT will bring healthcare insurance solutions to the business members.
HILB Group, one of Insurance Journal’s Top 25 ranked U.S. insurance brokers with over 2400 employee across more than 125+ branch locations in all 50 States. It partners with HIT to co-develop and distribute smarter, more transparent self-funded health benefit solutions to a much broader base of small and mid-size employers.
Baily Insurance, established in 1880, in its fourth -generation ownership. The agency has over 200 years of combined team experience. Licensed advisors partnering with multiple Carriers. Baily is a co-founder and key broker partner in Fusion Health Plans that provides better care services and tech-enabled solution. The collaboration with HIT will deliver faster underwriting, administration, and scalability.
THIS WEBSITE/NEWSLETTER IS OWNED SUBSIDIARY BY DEDICATED INVESTORS, LLC.
OUR REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATION PURPOSES ONLY. WE ARE ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION. WE HAVE BEEN COMPENSATED A FEE OF THRITY TWO THOUSAND FIVE HUNDRED USD BY PRIMETIME PROFILES LLC FOR A TWO DAY HIT AWARENESS CAMPAIGN BEGINNING ON 10/7 AND ENDING ON 10/8. NEVER INVEST IN ANY STOCK FEATURED ON OUR SITE OR EMAILS UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING OUR SERVICES, JOINING OUR SITE OR OUR EMAIL/BLOG LIST AS WELL AS ANY SOCIAL NETWORKING PLATFORMS WE MAY USE.PLEASE NOTE WELL: DEDICATED INVESTORS LLC AND ITS EMPLOYEES ARE NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER.RELEASE OF LIABILITY: THROUGH USE OF THIS WEBSITE VIEWING OR USING YOU AGREE TO HOLD DEDICATED INVESTORS LLC, ITS OPERATORS OWNERS AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS (MONETARY OR OTHERWISE), DAMAGE (MONETARY OR OTHERWISE), OR INJURY (MONETARY OR OTHERWISE) THAT YOU MAY INCUR. THE INFORMATION CONTAINED HEREIN IS BASED ON SOURCES WHICH WE BELIEVE TO BE RELIABLE BUT IS NOT GUARANTEED BY US AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. DEDICATED INVESTORS LLC ENCOURAGES READERS AND INVESTORS TO SUPPLEMENT THE INFORMATION IN THESE REPORTS WITH INDEPENDENT RESEARCH AND OTHER PROFESSIONAL ADVICE. ALL INFORMATION ON FEATURED COMPANIES IS PROVIDED BY THE COMPANIES PROFILED, OR IS AVAILABLE FROM PUBLIC SOURCES AND DEDICATED INVESTORS LLC MAKES NO REPRESENTATIONS, WARRANTIES OR GUARANTEES AS TO THE ACCURACY OR COMPLETENESS OF THE DISCLOSURE BY THE PROFILED COMPANIES. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED HEREIN AND ANY DECISION TO INVEST IN ANY SUCH COMPANY OR OTHER FINANCIAL DECISIONS SHOULD NOT BE MADE BASED UPON THE INFORMATION PROVIDED HEREIN. INSTEAD DEDICATED INVESTORS LLC STRONGLY URGES YOU CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES AND CONSIDERATION OF ALL PERTINENT RISKS. READERS ARE ADVISED TO REVIEW SEC PERIODIC REPORTS: FORMS 10-Q, 10K, FORM 8-K, INSIDER REPORTS, FORMS 3, 4, 5 SCHEDULE 13D.DEDICATED INVESTORS LLC IS COMPLIANT WITH THE CAN SPAM ACT OF 2003. DEDICATED INVESTORS LLC DOES NOT OFFER SUCH ADVICE OR ANALYSIS, AND DEDICATED INVESTORS LLC FURTHER URGES YOU TO CONSULT YOUR OWN INDEPENDENT TAX, BUSINESS, FINANCIAL AND INVESTMENT ADVISORS. INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AND EXTREMELY HIGH DEGREE OF RISK. IT IS POSSIBLE THAT AN INVESTORS INVESTMENT MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES INVESTORS A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT MAY BE FORWARD LOOKING STATEMENTS. FORWARD LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD LOOKING STATEMENTS IN THIS ACTION MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEE, EXPECTS, WILL, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, OR THAT BY STATEMENTS INDICATING CERTAIN ACTIONS & QUOTE; MAY, COULD, OR MIGHT OCCUR. UNDERSTAND THERE IS NO GUARANTEE PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS. IN PREPARING THIS PUBLICATION, DEDICATED INVESTORS LLC HAS RELIED UPON INFORMATION SUPPLIED BY ITS CUSTOMERS, PUBLICLY AVAILABLE INFORMATION AND PRESS RELEASES WHICH IT BELIEVES TO BE RELIABLE; HOWEVER, SUCH RELIABILITY CANNOT BE GUARANTEED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. THE ADVERTISEMENTS IN THIS WEBSITE ARE BELIEVED TO BE RELIABLE, HOWEVER, DEDICATED INVESTORS LLC AND ITS OWNERS, AFFILIATES, SUBSIDIARIES, OFFICERS, DIRECTORS, REPRESENTATIVES AND AGENTS DISCLAIM ANY LIABILITY AS TO THE COMPLETENESS OR ACCURACY OF THE INFORMATION CONTAINED IN ANY ADVERTISEMENT AND FOR ANY OMISSIONS OF MATERIALS FACTS FROM SUCH ADVERTISEMENT. DEDICATED INVESTORS LLC IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES ADVERTISED HEREIN, NOR IS DEDICATED INVESTORS LLC RESPONSIBLE FOR ANY OTHER PROMOTIONAL FIRM, ITS PROGRAM OR ITS STRUCTURE. DEDICATED INVESTORS LLC IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES EXCHANGE COMMISSION OR FINRA.
